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Chapter 1 
GENERAL INTRODUCTION
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1. Introduction
The application of oral implants in daily clinical practice has changed extremely the 
possibilities of oral rehabilitation.1 For example, a recent meta-analysis review2 indicated an 
estimated 5-year survival of implant supported bridges of 95 % and implant supported single 
crowns of 94%, while after 10 years of function the estimated survival decreased to 87% for 
implant-supported bridges and to 89% for implant-supported single crowns. The long-term 
success of oral implants requires rigid fixation of the implant within the host bone site. This 
condition, known as functional osseointegration, is achieved in various implant systems by an 
interlock between the implant surface and the bone tissue.1 Clinical and experimental studies 
have demonstrated that such a situation can only be achieved when implants are placed in 
bone of sufficient quantity and quality.3 There is strong evidence from clinical and 
experimental studies that there is an increased risk of implant failure when these specific 
conditions are not met.4,5 Impaired healing ability, poor bone characteristics, premature 
loading or overloading and infection are all considered as major etiological situations causing 
implant failure.6 Additionally, various studies indicated a higher rate of long-term implant 
loss in the maxilla in comparison to the mandible and it has been suggested that the amount 
and quality of maxillary bone is responsible for the higher rate of implant failure in this 
area.7,8 Also, there is skepticism about the use of implants in more demanding situations. For 
example, patients diagnosed with systemic diseases such as osteoporosis and diabetes 
comprise a compromised area of implant therapy.9 Further, the concept of immediate implant 
loading to reduce the discomfort, inconvenience, and anxiety of the patient remains a 
challenge.10 Clinical experience has also shown that implant failure often occurs at early 
stages after surgery, indicating the necessity of understanding the initial response of the 
surrounding tissues to the implant.11,12
All these above-mentioned reasons justify the necessity for ongoing research to investigate 
factors that may improve oral implant osseointegration, especially during the early post­
implantation healing phase. Several factors such as implant design, implant surface, surgical 
technique, bone type and loading conditions have been shown to influence implant 
osseointegration.4 Additionally, growth factors may also stimulate bone healing around 
medical and oral implants.13 These are powerful biological factors that can initiate bone 
formation in soft tissue and bone tissues and it can be speculated that they may be used to 
improve bone healing and implant integration. Particularly, growth factors released from blood 
platelets have been suggested for use to increase the rate of bone deposition in combination 
with oral implant placement.14
2. Platelet Rich Plasma
Platelet rich plasma (PRP) is a new approach in tissue regeneration and a developing area for 
clinicians and researchers (Figure 1). It is used in various surgical fields, including head and 
neck surgery, otolaryngology, cardiovascular surgery, as well as oral and maxillofacial 
surgery.15 Although the growth factors and mechanisms involved are still poorly understood, 
the easy application of PRP in clinical practice and its possible beneficial outcome, including 
bone regeneration, reduction of bleeding and rapid wound healing, holds promise for new 
treatment approaches. An important feature of PRP is that this autologous product, which is 
prepared from the patient’s own blood, eliminates concerns about immunogenic reactions and 
disease transmission.
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Figure 1: Number of publications in MEDLINE regarding the application of platelet-rich plasma in 
medical fields and especially in dentistry. A trend for increase is outlined during the last years.
Although basic clinical research has focused on the application of growth factors, the short 
shelf life and inefficient delivery to target cells are major concerns associated with local 
administration of recombinant human growth factors. Additionally, they are expensive and 
high doses may be required to achieve any therapeutic effect. An alternative, easy, cost- 
effective way to obtain high concentrations of growth factors for tissue healing and 
regeneration may be autologous platelet concentrates. In 1990, Gibble and Ness introduced 
fibrin gel, a biomaterial that includes haemostatic agents and has adhesive properties.16 PRP is 
an autologous modification of fibrin glue that has been described and used in various 
applications with promising clinical success.14,17 Different bioactive substances are released 
from platelets upon activation. Among them, platelet-derived growth factor (PDGF), trans­
forming growth factor (TGF), insulin-like growth factor (IGF) and epidermal growth factor 
(EGF) play a pivotal role in initiating and sustaining wound healing and tissue repair mech­
anisms.18
The aim of this literature review is to discuss the scientific evidence regarding the use of PRP 
in dentistry and to describe the different bioactive substances present in PRP and their 
participation in the healing process. Further, this review intends to elucidate the different 
techniques and available technology for PRP preparation and to clarify the possible risks of 
using PRP. Finally, this review discusses in vitro, animal and human studies published to date 
and provides guidance for future research.
3. Definition and biological properties of Platelet Rich Plasma
According to Marx et al. 1998, platelet-rich plasma is an autologous concentration of human 
platelets above baseline in a small volume of plasma.19 However, the preparation of 
allogeneic PRP (homologous) might not be excluded. As autologous PRP preparation requires 
blood to be drawn from the patient, the use of allogeneic platelet rich plasma may serve as an 
alternative option in the case of patients who refuse to be subjected to a venipuncture and 
blood drawing procedure.20
Normal platelet counts in human blood range between 150,000/^L and 350,000/^L with an 
average of about 200,000/^L. A concentration of 1,000,000/^L in a 5 mL volume of plasma 
has been suggested to be the ‘‘working definition of PRP’’ and lower concentrations may not
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enhance wound healing whereas higher concentrations have not shown further enhancement 
of wound healing.21
The properties of PRP are based on the production and release of multiple growth and 
differentiation factors upon platelet activation. These factors are critical in the regulation and 
stimulation of the healing process and they play an important role regulating cellular 
processes such as mitogenesis, chemotaxis, differentiation, and metabolism.22 However, the 
determinants for the biological properties of PRP are still unknown and there is insufficient 
understanding concerning the clinical effects of PRP application.14 The combined action of all 
these growth factors is very complex and each growth factor may have a different effect on a 
particular tissue. Growth factors may also interact with each other, leading to different 
multiple signaling pathways. Different isoforms of them have varying effects that may 
enhance or inhibit the osseous and soft tissue repair depending on the mode of growth factor 
release as well as the dynamics of the wound environment.23
4. Biological mechanism of PRP activity
Wound healing is a complex phenomenon related to various growth factors and many cell 
types that participate in this process. Disruption of the vasculature as a result of injury leads to 
fibrin formation and platelet aggregation. A stable blood clot is then formed by blood 
coagulation. Subsequently, several growth factors are released into the injured tissue from the 
platelets and other cells that induce and support healing and tissue formation.24 PRP behaves 
with the same manner and therefore, it is activated by the addition of thrombin and calcium 
chloride resulting in the release of a cascade of growth factors from the alpha granules.25 The 
secretion of these growth factors is initiated by the clotting process of PRP volume and begins 
within 10 minutes after clotting.21 More than 95% of the pre-synthesized growth factors are 
secreted within 1 hour.26 After the initial burst of PRP-related growth factors, the platelets 
synthesize and secrete additional growth factors for the remaining 7 days of their life span.26 
The interaction of these growth factors with surface receptors on the target cells activates an 
intracellular signaling pathway that induces production of proteins needed for the regenerative 
process such as cellular proliferation, matrix formation, osteoid production and collagen
synthesis.27
Additionally, PRP contains proteins such as fibrin, fibronectin, vitronectin and 
thrombospondin, known to act as cell adhesion molecules important for bone, connective
26 19,28tissue and epithelial cell migration. Monoclonal antibody studies , have confirmed the 
presence of growth factors like PDGF and TGF-P in the PRP preparation. Studies have also 
shown that adult mesenchymal stem cells, osteoblasts, fibroblasts, endothelial cells, and 
epidermal cells express the cell membrane receptors that are specific to the growth factors 
included in PRP.14 Therefore, it is suggested that the growth factors included in the platelet 
concentrates may activate several cell types involved in wound healing and induce soft tissue 
healing and bone regeneration.
5. Growth factors included in PRP
The growth factors released from the platelets29 include platelet-derived growth factor 
(PDGF), transforming growth factor-P (TGF-P), platelet-derived epidermal growth factor 
(PDEGF), platelet-derived angiogenesis factor (PDAF), insulin-like growth factor-I (IGF-I), 
and platelet factor 4 (PF-4).
Platelet-Derived Growth Factor was first found in platelets and especially in the alpha
30 31 32granules. PDGF can also be found in other cells, such as macrophages , endothelial cells , 
monocytes and fibroblasts33, as well as in bone matrix.34 Three isoforms exist: AA, BB and
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AB.35 The reason for three distinct forms remains unclear but differential binding by various 
receptor cells such as endothelium, fibroblasts, macrophage and marrow stem cells has been 
suggested.35 The most important specific activities of PDGF include angiogenesis and 
macrophage activation36, proliferative activity on periodontal ligament fibroblasts37, 
chemotaxis for fibroblasts and collagen synthesis.38 Furthermore, PDGF enhances the 
proliferation of bone cells.39
Transforming Growth Factor-ft has been referred as member of a super-family of growth and 
differentiation factors including the bone morphogenetic proteins.40 TGF -P has three 
different isoforms: P1, P2 and P3.41 TGF-P has been observed to promote extracellular matrix 
production42, to enhance the proliferative activity of periodontal ligament fibroblasts43, to 
stimulate biosynthesis of type I collagen and fibronectin and to induce deposition of 
bone matrix.44 TGF-P may inhibit osteoclast formation and bone resorption, thus favoring 
bone formation over resorption.45
Insulin-like Growth Factor-I is chemotactic for periodontal ligament fibroblasts and 
stimulates protein synthesis.38 IGF-I enhances bone formation by proliferation and 
differentiation of osteoblasts. 46,47 Application of IGF-I to the surface of rat molars promotes 
cementogenesis48 and in combination with PDGF, bone formation on implant surfaces is 
increased.49
Platelet-derived Epidermal Growth Factor was discovered by Cohen in 1962.50 It stimulates 
epidermal regeneration, promotes wound healing by stimulating the proliferation of 
keratinocytes and dermal fibroblasts and enhances the production and effects of other growth 
factors.14
Platelet-derived Angiogenesis Factor has the capacity to induce vascularization stimulating 
vascular endothelial cells.51 Several cytokines and growth factors up-regulate PDAF, 
including IGF-1, TGF-a, TGF-P, PDGF, PDEGF and interleukin 1b.
Platelet Factor 4 is also released from the a granules of platelets and may be partially 
responsible for the initial influx of neutrophils into wounds. It also acts as a chemoattractant 
for fibroblasts and may be a potent antiheparin agent.14
6. Required platelet concentration for PRP efficiency
Platelet concentrations ranging from 800 to 1200 x 109 platelets/L have been suggested to 
obtain an effective PRP dosage.52 A platelet count of 1000 x 109 platelets/L, as measured in a 
volume of 5 ml plasma, may be the "therapeutic dose" of PRP.26 On the other hand, Anitua 
and coworkers stated that platelet count of PRP should be more than 300 x 109 platelets/L.53 
Further, Choi and others showed that the viability and proliferation of alveolar bone cells 
were suppressed by high PRP concentrations, but were stimulated by low PRP concentrations 
(1-5%).54 Also, Arpornmaeklong and colleagues suggested that PRP inhibited osteogenic 
differentiation of pre-osteoblasts in a dose dependent manner.55 These reports support the 
view that variations in the PRP concentrations may influence the bone formation. 
Furthermore, Weibrich and others56 examined the platelet concentration among different 
donors and discovered that the platelet concentration of the PRP was correlated to the platelet 
count in the donor whole blood. They found also a significant effect of gender on platelet 
concentration, but no effect of age was detected.56
Some in vitro studies have examined the effective concentration level of the growth factors 
included in PRP. For example, Gamal and Mailhot57 indicated that the optimal concentration 
of PDGF-BB for inducing adhesion of periodontal ligament fibroblasts to periodontitis- 
affected root surfaces was 50 ng/mL. Regarding the concentrations of the growth factors 
present in the platelet concentrations, it was demonstrated58 that 1 ml of platelet lysates (109 
platelets/mL) contain 115 ng PDGF, 106 ng TGF-P, 20.8 ng FGF and 0.8 ng PDEGF
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determined by ELISA on 35 patients. Further, according to another study59, there are 
approximately 0.06 ng of PDGF per one million platelets.
7. Preparation of PRP
PRP can be prepared in a laboratory, a surgical or a dental room from blood collected in the 
immediate preoperative period. Especially for dental use, the preparation of small amounts of 
autologous PRP can be completed in minutes and involves limited stress. Each proper PRP 
device must use a double centrifugation technique. The blood sample is drawn into a tube 
with anticoagulation factor and then the tube is spun in standard centrifuge cycles. The first 
spin (hard spin) will separate the red blood cell from the plasma that contains the platelets, 
white blood cells and clotting factors (buffy coat).60 The second spin (soft spin) finely 
separates the platelets concentrate (PRP) from the platelet poor plasma (PPP). Office devices 
can use only 40 ml to 60 ml of blood and produce approximately 5-10 ml of PRP. This 
amount is adequate for most minor surgical procedures, including bilateral sinus grafts, ridge 
preservation or augmentation and periodontal regenerative therapies.17 However, in oral 
and maxillofacial reconstruction, up to 500 ml of whole blood should be drawn, in order to 
obtain the greater amounts of PRP needed for larger surgical defects.17 
The centrifugation process must be sterile and precisely suited to platelet separation from red 
blood cells attaining adequate concentrations of platelets.60 Therefore, not all currently 
commercial PRP devices may be equal and probably some do not concentrate active platelets 
in sufficient numbers to produce a healing enhancement.61 This may be an explanation of the 
variability regarding the clinical efficacy of PRP. Studies suggesting that there is no benefit 
from PRP may be based on poor-quality PRP produced by inadequate devices.26 Several 
commercial systems are available for preparing PRP such as the SmartPReP system (Harvest 
Autologous Hemobiologics, Norwell, Massachusetts, USA), the Tisseel system (Baxter Heath 
Corporation, Deerfield, Illinois, USA), the PCC System (Platelet Concentration Collection 
System, 3i Implant Innovations, Palm Beach Gardens, Florida, USA) and the Curasan PRP kit 
(Curasan, Pharma Gmbh AG, Lindigstrab, Germany). Appel and coworkers62 indicated that 
the PCC System and the Curasan PRP kit have greater ease of handling and shorter 
preparation times than the SmartPReP and the Tisseel system. Additionally, the Smart PReP 
system and the PCC System may produce the greatest platelet concentrations and higher level 
of growth factors.26
Several studies suggest different centrifugation cycles in terms of centrifugation time and 
force.14 The centrifugation force may be a critical step in PRP preparation and the applied 
mechanical forces may damage platelets, with the consequence of loosing the granular load of 
the growth factors. One study evaluated the effect of different centrifugal forces and showed 
that spins higher than 800g may decrease the amount of TGF-P that is released by the PRP.63 
There are also several choices of anticoagulants that can be used during PRP preparation. 
Anticoagulant citrate dextrose-A (ACD-A) is a preferable agent.21 The citrate binds calcium 
and prevents coagulation, while the dextrose and other ingredients support platelet 
metabolism and viability. Citrate Phosphate Dextrose (CPD) is also useful for PRP 
preparation. It is similar to ACD-A, but it has fewer supportive ingredients and therefore may 
be less effective in maintaining platelet viability.21 The use of EDTA is potentially more 
harmful than citrate in the preparation of PRP and high number of damaged platelets has been 
observed.64 Further, trisodium citrate solution is suggested as an anticoagulant with no 
negative effects on PRP preparation.65
At the time of application, the PRP is combined with a certain volume of a sterile saline 
solution containing 10% calcium chloride (a citrate inhibitor that allows the plasma to 
coagulate) and thrombin (an activator that allows polymerization of the fibrin into an
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insoluble gel, which causes the platelets to degranulate and release the indicated mediators 
and cytokines). Specifically, Sánchez and his colleagues proposed for the initiation of the 
coagulation process a mixture of 1,000 units (UI) of thrombin powder suspended in 10 ml of 
sterile saline with 10% calcium chloride.14 Anitua suggested that 50^L 10% calcium chloride 
should be added to a tube containing 1.2 ml of PRP and after 15 to 20 minutes a PRP gel can 
be formed without using thrombin.65
8. In vitro and animal studies that evaluate the effect of PRP.
Although platelet concentrates have been used to promote bone healing, the underlying 
cellular-level mechanisms remain poorly understood. The effect of PRP on bone cells may not 
be due to the action of a single growth factor but, instead, to the synergistic effects of the 
many growth factors derived from platelets. It has been shown that addition of either PDGF or 
TGF in cell cultures did not induce an enhanced cell proliferation similar to that observed in 
the presence of a platelet concentrate.66 Also, applying antibodies against PDGF suppressed 
only partially human bone cell proliferation induced by platelet-derived growth factors.67 
Soffer and coworkers investigated the effects of human platelet lysate (damaged platelets with 
microparticles of cytoplasmic and cell membrane and soluble growth factors) on rat calvaria 
bone cells.68 The results showed that short-term exposure to platelet lysate (up to 24 h) 
promoted the proliferative and chemotactic bone cell functions, while long-term exposure had 
a negative effect resulting in a decrease of both alkaline phosphatase activity and mineral 
formation. Another in vitro study also showed that PRP stimulated cell growth and 
differentiation of rat bone marrow cells up to 8 days.28 Furthermore, these results are in 
accordance with other reports that showed lysed platelet solutions stimulated the proliferation 
of human embryonic cells69 and had a mitogenic effect on bone cells derived from human 
trabecular67 and rat marrow adult bone.70 Therefore, the platelet-related activity may be not 
restricted to intact platelets, since microparticles of cytoplasmic and cell membrane produced 
from activated platelets may also stimulate human bone cell proliferation.67 These findings 
seem to be in disagreement with the statement of Marx’s studies21,26 that platelets damaged or 
rendered nonviable by PRP processing may not secrete bioactive growth factors resulting in 
disappointing outcomes.
However, in vitro studies use specific single cell lines with properties quite different from the 
developed cells functioning in the living human body. In addition, a lot of cell lines are often 
derived from other origins than human. This shortcoming extremely simplifies the real 
clinical situation where multiple growth factors and multiple cell types interact in a 
complicated manner making any extrapolation for the PRP efficacy quite doubtful.71 
Furthermore, several animal studies have provided encouraging results supporting the 
beneficial effect of PRP on bone healing in oral surgery.72 The use of platelet-rich plasma has 
been reported to improve the bone healing in rabbit calvaria defects 73,74 and to facilitate the 
incorporation of particulate cancelous bone grafts in goat mandibular reconstructions.75,76 
Another study assessed the efficacy of demineralized bone graft alone or combined with PRP 
in enhancing the osseointegration of dental implants in a dog model.77 The histomorphometric 
analysis revealed a higher percentage of bone contact in the test group. Furthermore, Kim and 
coworkers showed that bone defects around titanium implants can be treated successfully with 
particulate dentin-plaster of Paris, and that the outcome can be improved if PRP is also used.78 
On the other hand, there are also publications that concluded that there was little or no benefit 
from PRP. For example, in an animal study79, Aghaloo and others grafted 8-mm rabbit 
calvarial defects with autogenous bone, PRP alone, or autogenous bone and PRP; the control 
was no treatment. The histomorphometric evaluation showed a tendency for slightly more 
bone when PRP was combined with autogenous bone as compared to autogenous bone alone,
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but this difference was not significant. Also, Plachokova and coworkers showed that PRP had 
no effect on early bone healing in addition to an osteoconductive material (dense HA/P-TCP 
particles) in a rat model.80,81 Choi and others could not support any effect of PRP for bone 
formation in the mandible reconstruction of a canine model.82 Therefore, the analysis of the 
animal studies outlines the controversial nature of this issue and generates confusion 
regarding the effect of PRP in oral surgery.
9. Clinical studies that evaluate the effect of PRP.
In addition to other medical fields, PRP can be used, either alone or with bone substitutes, to 
promote bone healing in maxillofacial and periodontal surgery. 72
Anitua in 1999 reported that the application of PRP inside the extraction sockets improved 
soft-tissue repair and bone regeneration.65 The use of autologous platelets seemed to enhance 
bone autologous graft incorporation in sinus floor augmentation83 and showed improved 
results in the ridge preservation grafting.84 De Obarrio and others combined PRP with bone 
allograft and guided tissue regeneration for the periodontal therapy of human intrabony 
defects and they observed significant gain in clinical attachment, as revealed by 2-year follow- 
up but no control group was present.85 Petrungaro in 2001 published a case series in which 
PRP, subepithelial connective tissue grafts and collagen membranes were used to cover 
gingival recessions and the therapy was successful in all cases.86
On the other hand, in several human studies the use of PRP with grafts in sinus elevation87,88 
or in ridge augmentation89 did not enhance clinical results. The beneficial effect of PRP in 
sinus augmentation is also questioned by recent reviews.90,91 Huang and others did not 
observe any benefit adding PRP for root coverage treatment in a pilot human trial.92 Finally, 
no benefit was reported after PRP application combined with bone grafts and membrane in 
the treatment of periodontal intrabony defects.93,94
However, most of the human studies are case reports and to date only a few randomized 
control clinical trials dealing with PRP in oral surgery are available93-101 (Table 1). In 
summary, despite the majority of these studies reported a positive effect of PRP on alveolar 
bone formation, this effect is minimal to modest in the most of them. Additionally, PRP may 
have a short-time effect that extinguishes after three to six months.102
10. Risk of using Platelet Rich Plasma
Because PRP is prepared from autologous blood, it is inherently safe and any concerns of 
disease transmission such HIV, hepatitis and Cruetzfeld-Jacob disease (CJD) or immunogenic 
reactions that exist with allograft or xenograft preparations are eliminated.14 However, the 
preparation of PRP involves isolation of the PRP, after which gel formation is accelerated 
using calcium chloride and bovine thrombin. The use of bovine thrombin has been reported to 
be associated with the development of antibodies to factors V and XI and resulting in the risk 
of life-threatening coagulopathies. Landesberg and coworkers in 1998 reviewed reports 
appearing in the literature of serious coagulopathies that were difficult to treat following 
exposure to bovine thrombin.103 The bovine thrombin preparations contain factor V, which 
results in reaction of the human immune system when challenged with a foreign protein. The 
factor V deficiency after thrombin exposure may be caused by the cross-reactivity of anti­
bovine factor V antibodies with human factor V. To date, bovine thrombin-induced 
coagulopathies have been reported in 32 cases of patients undergoing cardiovascular 
operations, specifically in those patients with repeated exposure.104 The severity of bleeding 
varies widely, from no clinical evidence to life-threatening diatheses developing 7 to 14 days 
after successive exposure to bovine thrombin. However, the adverse reactions reported could
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Table 1: summaryof clinical studies that have used PRP
Authors Year Treatmentoption
Number
of
patients
PRP preparation technique
Follow-
up
period
(mths)
Main results Effect of PRP
Oral­
Marx et al. 1998 maxillofacial 
reconstructions
8 8
Centrifugation steps: 5600 
rpm & 2400 rpm, time is not 
mentioned
PRP activator: bovine 
thrombine & calcium chloride 
Device: Medtronic 
Electromedics, Inc., 
Minneapolis, MN, USA.
The use of PRP 
resulted in an 
additional 
mean bone 
formation of 
19%
Strong
Anitua 1999
Bone
augmentation
prior
implantation
centrifugation steps: 160g for 
6  min
20 PRP activator: Calcium
chloride
Device :not mentioned
The use of PRP 
resulted in 
complete bone 
maturation of 
80% of the 
cases
Strong
Wiltfang et al. 2003 Sinusaugmentation 35
Hanna et al. 2004
Intrabony defect 
resolution
13
Centrifugation steps: not 
mentioned
PRP activator: not mentioned 
Device :Curasan kit, Curasan 
Pharma GmbH, Kleinostheim, 
Germany
Centrifugation steps: not 
mentioned
PRP activator: bovine 
thrombin & calcium chloride 
Device :SmartPrep, Harvest 
Technologies Co., Plymouth, 
MA, USA
The use of PRP 
resulted in an 
additional 
mean bone 
formation of 
8 %
Modest
The use of PRP 
resulted in an 
additional
mean probing Modest
pocket
reduction of
1 . 0  mm
Oyama et al.
Oral-
2004 maxillofacial 
reconstructions
1 2
centrifugation steps: 160g for 
2 0  min & 4 0 0 g for 1 5  min 
PRP activator: Fibrin glue 
Device:not mentioned
The use of PRP 
resulted in an 
additional 
radographic 
bone density of 
16.5%
Strong
Kassolis & 
Reynolds
2005 Sinus
augmentation
Centrifugation steps: not 
mentioned
PRP activator: calcium 
1 0  chloride
Device:SmartPrep, Harvest 
Technologies Co., Plymouth, 
MA, USA
4 to 6
The use of PRP 
resulted in an 
additional 
mean bone 
formation of 
6 . 8 %
Weak
Okuda et al.
Intrabony defect 
2005 resolution 70
Centrifugation steps: 2 4 0 0  
rpm for 1 0  min & 3600 rpm 
for 1 5  min
PRP activator: sodium 
alginate
Device: not mentioned
1 2
The use of PRP 
resulted in an 
additional 
mean probing 
pocket 
reduction of 
1 . 0  mm
Modest
6
4
6
6
6
18
Raghoebar et 
al.
Sammartino et 
al.
Thor et al.
Consolo et al.
Dori et al.
Dori et al.
Centrifugation steps: 2 4 0 0  rpm for 1 0  
min & 3600 rpm for 1 5  min 
2 0 0 5  Sinus 5  PRP activator: calcium chloride
augmentation Device: PCCS, 3i Implant
innovations, Palm Beach Gardens,
FL, USA
3
Intrabony 
2005 defect
resolution
Centrifugation steps: 1200 rpm for 15 
min
18 PRP activator: batroxobine & 
calcium gluconate 
Device: not mentioned
3
2005
Bone
augmentation
prior
implantation
Centrifugation steps: 5600 rpm & 
2400 rpm, time is not mentioned 
19 PRP activator: calcium chloride 
Device: Medtronic Electromedics, 
Inc., Minneapolis, MN, USA.
1 2
centrifugation steps: 1 2 0 0 g for 6  min 
& 4 4 0 0 g for 6  min 
2 0 0 7  Sinus . 6  PRP activator: Calcium chloride 4  7
2 0 0 7  augmentation 1 6  Device:RC3C, Sorval, Thermo 4  to 7
Electron Corporation,Waltham, MA,
USA
Intrabony 
2007a defect
resolution
30
Centrifugation steps: 2400 rpm for 10 
min & 3600 rpm for 15 min 
PRP activator: bovine thrombin & 
calcium chloride
Device: Curasan kit, Curasan Pharma 
GmbH, Kleinostheim, Germany
12
Intrabony 
2007b defect
resolution
30
Centrifugation steps: 2400 rpm for 10 
min & 3600 rpm for 15 min 
PRP activator: bovine thrombin & 
calcium chloride
Device: Curasan kit, Curasan Pharma 
GmbH, Kleinostheim, Germany
1 2
The use of PRP did 
not resulted in any 
significant 
difference in terms 
of % bone 
formation
The use of PRP 
resulted in an 
additional mean 
probing pocket 
reduction of 3.2 
mm
The use of PRP did 
not resulted in any 
significant 
difference in terms 
of implant failure, 
implant stability or 
bone resorption
The use of PRP 
resulted in an 
additional mean 
bone formation of 
17% in 4 months, 
whereas in 7  
months no 
significant 
difference was 
observed
The use of PRP did 
not resulted in any 
significant 
difference in terms 
of probing pocket 
reduction
The use of PRP did 
not resulted in any 
significant 
difference in terms 
of probing pocket 
reduction
None
Strong
None
None
None
None
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depend upon an increased awareness of the coagulopathy, as well as the source and quantity 
of thrombin used. Also, differences in product purity have been documented. One brand of 
thrombin (Thromhin-JMI, Jones Medical Industries, St. Louis, USA) applies an extra 
purification step to decrease the factor V concentration from 50 mg/mL (until 1997) to less 
than 0.2 ^g/mL. In addition, the bovine thrombin preparations used in the reported cases were 
high dose (>10,000 units) and were applied directly onto open wounds where absorption into 
the systemic circulation is certain. The use of bovine thrombin in PRP is low dose (<200 
units), is topical with no entry into the systemic circulation, and is already clotted when it 
comes into contact with human tissues. It is therefore not absorbed systemically but is 
engulfed and digested by the macrophages that also digest the clot itself. Based on the 
reported coagulopathies, Landesberg and coworkers64 described a new method to activate 
PRP gel with the ITA gelling agent (Natrex Technologies, Greenville, NC, USA). They stated 
that this method could be used more safely as an alternative to bovine thrombin for gelling the 
PRP, although they did not describe the specific composition and mechanism of action of 
ITA. On the other hand, some authors proposed that PRP gel formation can be performed 
only with the addition of calcium and no thrombin is required.63,65
11. Conclusion
In summary, it is still unclear to what extent the use of PRP may affect the bone regeneration 
process compared to other treatment modalities in oral surgery. Based on the inconclusive 
results in the current dental literature, this review cannot provide solid evidence in favor of 
the application of PRP in oral surgery. However, since the majority of the reviewed articles 
reported encouraging outcomes, further trials are necessary to elucidate the effect of PRP on 
oral surgery. Well-designed studies are needed to provide solid evidence on the capacity PRP.
12. Thesis objectives
As discussed before, previous research indicates that biological factors as present in Platelet 
Rich Plasma may enhance bone healing and accelerate bone formation. Therefore, the aim of 
the current thesis was to elucidate the effect of Platelet Rich Plasma on bone formation and to 
investigate whether growth factors which are present in Platelet Rich Plasma can improve the 
bone response to oral implants, especially during the early post-implantation healing phase. 
The hypothesis of the current research is that the growth factors as available in PRP can 
enhance the bone apposition on the implant surface.
In view of the above mentioned, the specific objectives of the thesis were the following:
1. to review systematically the effect of Platelet Rich Plasma on the bone regeneration in 
oral surgery and specifically in implant dentistry (chapter 2)
2. to evaluate the effect of Platelet Rich Plasma on the early bone healing around calcium 
phosphate coated and uncoated oral implants installed in the trabecular bone of the 
femoral condyle of goats (chapter 3)
3. to investigate the effect of Platelet Rich Plasma on the early bone healing around calcium 
phosphate coated and uncoated oral implants installed in the tibial cortical bone of goats 
(chapter 4)
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4. to study whether the addition of Transforming Growth Factor-p1 (a growth factor as 
present in PRP) can enhance the early bone formation around oral implants installed in the 
trabecular bone of the femoral condyle of goats (chapter 5)
5. to assess the effect of Platelet Rich Plasma on bone formation in a human case (chapter 6)
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1. Introduction
Platelet-rich plasma (PRP) is defined as an “autologous concentration of platelets in a small 
volume of plasma” (Marx 2004) and is considered to be a rich source of autologous growth 
factors. It was first introduced in 1998 by Marx and coworkers, in combination with 
autogenous bone grafts for reconstruction of mandibular defects (Marx et. al 1998). Their 
study showed that the addition of PRP to bone grafts resulted in a faster radiographic 
maturation rate and higher bone density than bone grafts alone. Since then, the effect of PRP 
on bone regeneration has been extensively investigated. In the field of dentistry PRP has been 
used in different clinical procedures (i.e. sinus floor elevation, alveolar ridge augmentation, 
mandibular reconstruction, maxillary cleft repair, treatment of periodontal defects and 
treatment of extraction sockets), where it has been applied alone or in addition to autogenous 
bone, anorganic bone mineral and organic bone substitues. Many papers reported positive 
effects of PRP on bone formation (Whitman et al. 1997, Kassolis et al. 2000, Camargo et al.
2002, Lekovic et al. 2003, Fennis et al. 2004, Nikolidakis et al. 2006). On the other hand, 
limited or no beneficial effect has also been shown (Froum et al. 2002, Monov et al. 2005, 
Raghoebar et al. 2005, Thor et al. 2005, Plachokova et al. 2006).
The contribution of PRP to the bone healing process is thought to be based on the growth 
factors (GFs) stored in it. The following GFs are reported to be present in PRP: platelet 
derived growth factor (PDGF), transforming growth factors-P (TGF-P), vascular endothelial 
growth factor (VEGF), epithelial growth factor (EGF), insulin growth factor-1 (IGF-1), basic 
fibroblast growth factor (bFGF), as well as three blood proteins known to act as cell adhesion 
molecules for osteoconduction: (i.e. fibrin, fibronectin and vitronectin) (Tozum& Demiralp
2003, Sanchez et al. 2003). Therefore, PRP may influence bone formation through a variety 
of pathways.
The basic hypothesis of PRP addition to bone grafts is that high concentrations of platelets in 
a bony wound will increase the local concentration of secreted growth factors and 
subsequently enhance initial bone healing response. Later on, the direct influence of PRP will 
fade away and physiological mechanisms of bone repair will continue to work on an 
accelerated level (Jakse et al. 2003).
Currently, there is a lack of scientific evidence in the dental literature in favour for or against 
the clinical use of PRP for bone regeneration. Several reviews on the application of PRP in 
dentistry have been published (Schilephake 2002, Soffer et al. 2003, Tozum& Demiralp 2003, 
Sanchez et al. 2003, Marx 2004, Freymiller & Aghaloo 2004, Grageda 2004), but none of 
them followed a systematic approach. The aim of this systematic review is to determine and 
to structurally analyze the reported effects of PRP on bone regeneration in humans. For this 
purpose all clinical PRP applications in the field of dentistry are considered.
2. Materials and Methods
A protocol was set-up prior to commencing the review, including agreements on search 
strategy, study inclusion criteria, data extraction, and statistical analysis. The literature was 
searched for references published up to June 2006 in MEDLINE and Cochrane Central 
Register of Controlled Trial databases. Three search terms - "platelet-rich plasma", "bone 
regeneration" and "dentistry"- were used together with their all known synonym s. “Bone 
regeneration” and “dentistry” were applied as MeSH terms, all the others as free-text terms. 
As a result, the following combinations were made: "platelet rich plasma" OR "platelet-rich 
plasma" OR "PRP" OR "autologous platelet gel" OR "plasma-rich growth factors" OR 
"autologous platelet concentrate" OR "platelet concentrates" AND "bone regeneration" OR 
"bone healing" AND "dentistry". Abstracts of these references were read and controlled
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clinical trials meeting specific criteria were identified. Studies were included only if these (a) 
reported treatment outcomes (either by clinical, radiographic or/and histological measures) of 
PRP and controls on bone healing, (b) included at least 5 patients, and (c) had a follow-up of 
at least 3 months. Only papers written in English were considered. Papers not meeting all 
criteria were excluded. If no abstract was available in the databases, the abstract of the printed 
article was used. If title and abstract did not provide sufficient information to assess the 
eligibility of the paper, the full report was obtained as well. In addition, reference lists of 
previous published reviews were searched to detect additional studies. The search was carried 
out by two readers (A.P. & D.N.) independently. Disagreements were resolved by discussion.
In the following step the selected articles were printed and once again assessed by the two 
readers for the same inclusion criteria. For this purpose only Materials and Methods, and 
Results sections were used. Reference lists of papers included were checked by hand and 
cross-matched with the original list of references in order to detect additional studies that met 
the inclusion criteria. Relevant data (e.g. study design, patients’ characteristics, methods of 
PRP preparation, clinical outcomes, evaluation period) were extracted. Furthermore, study 
quality was assessed according to key quality components of controlled trials. Definitions for 
the quality assessment items were derived from two guidelines for systematic reviews 
(Cochrane Reviewers' Handbook, 2001; NHS Centre for Reviews and Dissemination, 2001, 
and Montenegro et al. 2002).
Cohen’s Kappa-coefficient was used as a measure of agreement between the two readers in 
each step. Outcomes of the interventions in each study were compared. For this purpose 
Means and Standard Deviations (SD) or Standard Errors (SEM) drawn from each study were 
used to calculate Confidence Intervals (CI). The statistical analysis was performed by means 
of a commercially software program (SPSS for Windows version 12.0, SPSS Inc, Chicago, 
IL, USA).
3. Results
The PubMed and Cochrane search resulted in 108 hits. From assessing the titles and abstracts, 
91 were excluded (inter-reader agreement k=0.89±0.06) and finally, 17 articles were accepted 
for further analysis. One paper appeared to be irretrievable (Simon et al. 2004) resulting in 
sixteen articles remained to be read. Reading Materials and Methods and Results sections of 
the articles revealed 9 papers fulfilling the inclusion criteria (inter-reader agreement k=1). 
Seven studies were excluded in this step: three of them were reviews and four had no control 
group. The hand search did not reveal additional studies to be included. All papers selected in 
the first selection step and the studies remaining after the second selection are presented in 
Table 1.
Table 2 shows the extracted data according to different treatment modalities. A substantial 
heterogeneity in the studies existed with regards to patient populations, study designs, PRP 
preparation techniques, outcome measures and observation periods. The studies that reported 
similar outcome measures (i.e. clinical attachment level and percentage of new bone 
formation) were compared using the calculated Confidence Intervals (CI): Figures 1 and 2. 
PRP treatments of periodontal defects were significantly more effective compared to their 
controls in two studies (Okuda et al. 2005, Sammartino et al. 2003). In the study of Hanna et 
al. 2004 the difference was very small and there was overlap of CIs.
With respect to the use of PRP in sinus elevation, one study (Raghoebar et al. 2005) reported 
no difference compared to the control. The study of Wiltfang et al. 2003 reported a positive 
effect of 9%, but there was a substantial overlap in the CIs. Overall, no significant difference 
in the treatment outcome was observed between sinus elevation procedures with and without 
PRP.
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Table 3 presents the outcomes of the study quality assessment (inter-reader agreement k =
0.90 ± 0.04). Overall, the majority of them do not meet current recommendations on study 
quality related to sample size calculation, randomization methods, allocation concealment, 
examiner blinding, validity of statistical methods, as well as validity of outcomes and 
estimation.
4. Discussion
This systematic review aimed to assess the available scientific evidence for applying PRP for 
bone regeneration in all fields of dentistry. The inter-reader agreements for inclusion of 
papers and quality assessment are unusually high (i.e. first step k= 0.89 ± 0.06, second step k 
= 1, quality assessment k=0.90 ± 0.04) most probably because both readers are well 
acquainted with the subject of PRP (Plachokova et al. 2006, Nikolidakis et al. 2006). 
Unfortunately, no statistical analysis of the data was possible due to the heterogeneity of the 
studies. However, the present study is considered a qualitative systematic review since 
rigorous methods for outcome assessment were applied (Sutherland 2004). At the same time, 
a risk of publication bias has to be mentioned, since English language was used as a limit by 
the literature search. Moreover, unpublished data as well as commercial interests in the 
studies were not explored.
Table 1: Papers selected after first selection (in alphabetical order, n=17), papers remaining after second selection are presented in italics
(n=9)
References Reasons for exclusion
Anitua 1999
Anitua 2006 Absence of control group, combined human & animal study
Camargo et al. 2002 Absence of control group, improper study design to draw conclusions about 
PRP efficacy
Garg et al. 2000 Not a clinical trial (review)
Garg et al. 2000 Not a clinical trial (review)
Hanna et al. 2004
Kassolis & Reynolds 2005 Improper control group
Marx et al. 1998
Okuda et al. 2005
Oyama et al. 2004
Raghoebar et al. 2005
Sammartino et al. 2005
Simon et al. 2004 Irretrievable
Steigmann & Garg 2005 Absence of control group
Thor et al. 2005
Watt-Smith 2005 Not a clinical trial (review)
Wiltfang et al. 2003
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Table 2: Comprehensive presentation of selected studies (n=9)
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Study P R P
N
Control 95% Cl
N
M ean values and 95% C l
Wiltfang eta l 2003 17 9 0(3.3,14.7) 18 0 (-6.3,6 3) 
Kassolis & Reynolds et al. 2005 10 6.8 (-1.2, 14.8) 10 0 (-4.8, 4.8) 
Raghoebar et al. 2006 5 -2.7 (-13.6,8.2) 6 0 (-8.0,8.0)
Evaluatioi
period
-20 -15 -10 +5 +10 +15 +20
Figure 1: Comparison of the Mean values and 95% Confidence Intervals for test and control groups 
of the selected studies performed for treatment of periodontal defects. The results of ACAL in mm are 
presented. The means of the controls were set on 0. Plus (+) values show favorable effect of PRP.
Figure 2: Comparison of the Mean values and 95% Confidence Intervals for test and control groups 
of the selected studies performed for sinus elevation. The results of bone formation in % are presented. 
The means of the controls were set on 0. Plus (+) values show favorable effect of PRP.
An attempt was made to compare results from the studies that used similar outcome measures 
by adding Confidence Intervals to the data presented in the original papers (Figure 1 and 
Figure 2). On one hand, it was not allowed to pool these data because of different follow-up 
periods. On the other hand, the similar and objective presentation of the measured outcomes 
from the different studies enabled a relative comparison. Differences in treatment effects for 
periodontal defects in terms of clinical attachment level (CAL) were significant, the mean 
differences ranging from 0.8 to 3.2 mm, however, the differences in the CI in two out of tree 
studies appeared to be small (Hanna et al. 2004 and Okuda et al. 2005). An explanation for 
the superior results of Sammartino et al. 2005 (above the rest of the studies) could be the 
shorter evaluation period used (3 months versus 6 and 12 months). PRP is supposed to have 
an effect on the early stages of bone formation, therefore it can be speculated that at later time 
points this effect diminishes or does not exist any more. Besides that, PRP in the study of 
Sammartino et al. 2005 was used to treat periodontal defects caused by the complications of 
mesioangular impacted mandibular third molars, whereas in the studies of Hanna et al. 2004 
and Okuda et al. 2005 PRP was applied in defects caused by periodontal disease. In addition,
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the age effect of the patients enrolled in the studies, as a factor influencing the treatment 
outcomes, can not be excluded. For example, in the study of Sammartino patients’ ages 
ranged between 21 and 26, whereas Hanna’s patients ranged between 35 and 75 years. In 
contrast, the mean patient age as reported by Okuda et al. 2005 was 55.5±8.2.
Table 3: Quality assessment of selected studies (n=9)
Quality assessment items* Yes/Adequate
n
No/Inadequate
n
Unclear
n
Sample size calculation described 9
Described as controlled 8 1
Described as randomized 6 3
Randomization methods 1 4 4
Allocation concealment method 1 8
Examiner blinding 6 1 2
Patients follow-up 9
Validity of statistical methods 5 1 3
Validity of outcomes and estimatition 4 1 4
n =number of studies
*definitions were adopted from Montenegro et al. (2002)
Another explanation for the overall positive effects as reported in the periodontal studies can 
be the used assessment methods (CAL and PD measurements). It is known that besides to 
bone formation, gain in CAL is due to formation of connective tissue fibres and a long 
junctional epithelium. Since it is claimed that PRP has also stimulatory effect on fibroblasts 
(Marx et al.1998), the PRP enhanced connective tissue proliferation can have caused the 
positive changes in the outcome measures. Clinically it is impossible to discern how much of 
the gain in CAL is due to bone formation and how much to connective tissue formation. Only 
histological evaluation can provide this information. Unfortunately, re-entry procedures to 
obtain histological samples are not a routine practice, especially when periodontal 
regeneration is aimed. In this context, it has to be noticed that Zybutz et al. 2000 compared 
clinical (PD and CAL) and radiologic measurements of intrabony defects with direct bone 
measurements during surgical procedure, and concluded that probing attachment level 
measurements (CAL) are an accurate method to assess bone level and can be reliably used to 
evaluate bone level changes after treatment (Zybutz et al. 2000). This finding validates the
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conclusions of the above mentioned studies, which results are based only on the changes of 
CAL and PD over time. However, it has to be emphasized that histological evaluations are 
needed to confirm the bone regenerative effect of PRP.
In view of the sinus elevation procedures, the reported effects of PRP (compared to their 
controls) were less than 10%, Moreover, there was a wide variety in outcome which is 
demonstrated by the large Confidence Intervals (> 10%). Consequently, the evidence for a 
beneficial effect of PRP in sinus elevation is considered to be weak. This corroborates the 
conclusions of the review of Boyapati and Wang (Boyapati & Wang 2006). Based on animal 
and human studies they concluded that the additional use of PRP in sinus augmentation could 
not be recommended.
Overall, the majority of the reviewed studies reported a positive effect of PRP for bone 
regeneration. However, the quality assessment of these studies, judged by their reports, 
revealed that most of them do not meet current recommendations on study quality. Study 
designs, randomization methods, concealments of the allocation sequence and blinding of 
examiners could not be judged adequately. In some studies the validity of outcomes and 
estimation was found unclear or even inadequate. If these methods are not implied or properly 
executed in the actual study conduct, outcomes of these trials can be biased. Inadequate or 
unclear methods were found to exaggerate the treatment effect compared with adequate 
methods (Juni et al. 2001; Colditz et al. 1989). In view of the above mentioned, the data 
provided by poor quality studies, as judged by their publications, cannot be used as evidence. 
To increase evidence, better reporting of clinical trials on PRP is required, and the CONSORT 
statement (Moher et al. 2001b) is suggested as a helpful guide for improving study quality.
A substantial heterogeneity among the studies was observed in the current review. One of the 
reasons is the difference in protocols as used for PRP production. Some studies used 
commercially available platelet-concentrating separators (FDA approved and/or European 
recognized) for PRP production, others used medical general-purpose cell separators. It has 
been claimed that the latter can be acceptable only when a standardized, two step spin 
procedure is followed. Single-spin machines have been reported to be incapable of separating 
and concentrating platelets to a therapeutic level (Marx & Garg 2005). Some of the included 
studies using the non-FDA-approved devices failed to provide a detailed description of the 
protocol for PRP production. In general, preferably this description should include 
information about the cell-separator used (name company, country,) centrifugation steps 
(rotations per minute, g/minutes), amount of blood collected preoperatively, baseline number 
of platelets in the collected blood, amount of PRP obtained, number of platelets in the 
obtained PRP (increase above baseline). In addition, the use of coagulation promoters (doses, 
mixing ratio to PRP) is considered indispensable information. In the current systematic 
review papers were not excluded for this reason since the omissions in the descriptions were 
only limited. However, the inclusion of above mentioned parameters has to be recommended. 
In summary, evidence was found for the use of PRP in periodontal defects. The evidence 
available in the dental literature for beneficial effects in sinus elevation is weak. No 
conclusions can be drawn about PRP for other applications in dentistry.
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1. Introduction
A major advance in dentistry has been the replacement of lost natural teeth by oral implants. 
The predictability and long-term success of oral implants are well documented.1,2 On the other 
hand, the success rates have been reported to vary among patients and several factors such as 
implant design, implant surface, surgical technique, bone type and loading conditions have 
been shown to influence implant osseointegration.3 Numerous studies have shown that the 
success rate of implants in local host bone with poor osteoregenerative potential is low.4 In 
view of this, Lekolm and Zarb (1985) have described four types of bone density (I-IV).5 The 
survival rate of oral implants placed into type IV bone is dramatically decreased compared to 
other types.6 Furthermore, clinical experience has shown that implant failure occurs at 
relatively early stages after surgery.
Considering the effect of implant surface characteristics on the bone response7, two different 
categories of qualities can be discerned, i.e.: 1) topography, and 2) physicochemistry. The 
topographic features of the implant surface are related to the degree of the surface roughness. 
Moderate values of surface roughness (Sa: 1-2 p,m) evoke an enhanced bone response 
compared with lower or higher values.7 The use of calcium phosphate (Ca-P) coatings has 
also been shown to benefit the bone response during the initial healing period after implant 
insertion.8 Various animal studies proved that Ca-P coated implants show a higher amount of 
bone contact compared with non-coated implants.9,10
In addition to surface quality, growth factors can also stimulate bone healing around implants. 
The effect of osteoinductive factors like Bone Morphogenetic Proteins or Transforming 
Growth Factor-P has already been a topic of various experiments.11,12 The disadvantage of 
these growth factors is that they are expensive and that still concern exists about their safety 
in human administration.13 Alternatively, platelet rich plasma (PRP), which is a volume of 
autogenous plasma that has a platelet concentration above baseline, is a proven source of 
growth factors.14 Growth factors released from platelets15 include platelet-derived growth 
factor (PDGF), transforming growth factor-P (TGF-P), platelet-derived epidermal growth 
factor (PDEGF), platelet-derived angiogenesis factor (PDAF), insulin-like growth factor I 
(IGF-I), platelet factor 4 (PF-4). The positive impact of PRP is attributed to the angiogenetic, 
as well as cell proliferative and differentiating influence of TGF-P and PDGF, which are 
present in PRP in high concentrations.16 As PRP is developed from autologous blood, it is 
inherently safe and free from transmissible diseases. This distinguishes PRP from 
recombinant growth factors that are not native.17 To date, PRP has been mainly used as a bone 
graft enhancement material and thus there is limited evidence to support the use of PRP in 
combination with dental implant placement.18,19
Further, PRP is usually applied as a gel by mixing the PRP immediately before use with 
calcium chloride and bovine thrombin. However, the use of bovine thrombin has been 
reported to be associated with the development of antibodies to factors V and XI, which can 
result in the risk of life-threatening coagulopathies.20 Therefore, Dugrillon et al. proposed 
already the formation of PRP gel by the addition of calcium without using thrombin as 
activator.21
Considering the above mentioned, the purpose of the present study was to investigate the 
effect of local application of autologous PRP on the trabecular bone healing around oral 
implants with two different surface qualities, i.e. a Ca-P coated surface and a non-coated 
titanium surface with almost similar roughness. In addition, PRP was applied by gel 
preparation by mixing the PRP fraction with calcium chloride solution and bovine thrombin 
followed by subsequent installation in the implant site, or via dipping of the implant in the 
PRP fraction before its insertion without using any additional agent.
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2. Material and methods
Implant preparation
Thirty-six (36) cylindrical commercially pure titanium implants with a diameter of 3.4 mm 
and length of 9 mm were used. They were grit-blasted with Al2O3 particles and then they 
were acid-etched (mixture of hydrochloric acid and sulfuric acid) for 1 minute and cleaned 
ultrasonically in isopropanol and dried at 100°C. Subsequently, half of the implants were 
provided with a thin CaP coating.
The CaP coatings were applied by using a commercially available RF magnetron sputter 
deposition system (Edwards ESM 100, Sussex, UK). The thickness of the CaP sputter coating 
was 1^m. After deposition, the coated specimens were subjected to an additional heat 
treatment (HT) for 2 hours at 550°C.
The physicochemical analysis showed that the heat-treated coatings had a crystalline apatite­
like structure with a Ca/P ratio of 1.8-2.0. Surface roughness measurements, using a Universal 
Surface Tester (UST, Innowep GmbH, Wurzburg, Germany), revealed that the roughness (Ra) 
value for the non-coated implants was 2.1 p,m, whereas the HA-coated implants showed Ra 
value of 2.3 p,m. Scanning electron microscopy (SEM) revealed that the non-coated titanium 
implants had a surface morphology with sharp peaks, whereas the surface of the CaP-coated 
implants had a smooth globular appearance (Fig. 1).
Finally, all implants were cleaned ultrasonically for 10 minutes to remove any loose particles 
and sterilized in an autoclave.
(a) (b)
Figure 1: The final roughness for the non-coated implants was Ra = 2.1 m^ (a), 
whereas the final roughness for the CaP-coated implants was Ra = 2.3 m^ (b).
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Procedure o f PRP preparation and application 
The PRP fraction was obtained from venous blood of goats one day before implant 
placement. Therefore, 250 cm3 of blood was drawn and centrifuged at a transfusion laboratory 
(SanQuin, Nijmegen, The Netherlands) in various cycles.22 Finally, 7.5 ml of platelet-rich 
plasma suspension was obtained (Table 1). Counting of the platelet concentration was also 
performed (platelet count exceeding 800 x 106/ml).
The final application of the PRP fraction was performed via gel preparation and subsequent 
installation in the implant site, or via dipping of the implant in PRP liquid before its insertion. 
The PRP gel was obtained at the time of surgery by mixing the PRP fraction with 10% 
calcium chloride solution and 300 IU of bovine thrombin (Fibriquick®, Organon Teknika, 
Boxtel, The Netherlands). The PRP liquid was used purely without addition of any agent.
Table 1: The volume and the platelet concentration of PRP harvested from each goat.
Goat PRP volume Platelets count
1 7,5 ml 1200 x 109 / ml
2 7,5 ml 800 x 109 / ml
3 7,5 ml 1000 x 109 / ml
4 7,5 ml 800 x 109 / ml
5 7,5 ml 1000 x 109 / ml
6 7,5 ml 1200 x 109 / ml
Animal model and implantation procedure
Six healthy mature female Saanen goats, weighing about 60 kg were used in this 
Before surgery, blood samples of the goats were taken to ensure that the animals 
CAE/CL arthritis free. The goats were housed in a stable and national guidelines 
use of laboratory animals were observed. The surgical procedure was performed under 
general anesthesia and was induced by an intravenous injection of pentobarbital and 
maintained by isoflurane 2-3% through a constant volume ventilator via an endotracheal tube. 
During operation, the goats were connected to a heart monitor.
Also, they received antibiotic prophylaxis to reduce perioperative infection risk according to 
the following scheme:
• During the operation: Albipen® 15%, 3 ml/50 kg s.c.
• 1 day after operation: Albipen® LA, 7.5 ml/50 kg s.c.
• 3 days after operation: Albipen® LA, 7.5 ml/50 kg s.c.
The implants were inserted into the left and right distal femoral condyles of the goat. For the 
insertion of the implants, each animal was immobilized on its back and the hind legs of the 
goats were shaved, washed and disinfected with povidone-iodine. A longitudinal incision was 
made on the medial surface of the left and right femur and the medial condyle was exposed. 
After exposure of the femoral condyle, three pilot holes were drilled (1.6 mm), which were 
gradually widened with different drills to the final diameter of the implant (3.4 mm). The 
distance between the three drill holes was always at least 1 cm. The bone preparation was 
performed with a very gentle surgical technique using a low rotational drilling speed (maxi­
mum 450 rpm) and continuous internal cooling. After bone preparation, the holes were 
irrigated with sterile water. After press-fit insertion of the implants, the soft tissues were 
closed in separate layers using resorbable Vicryl 3-0 sutures. A total of 36 implants were
study.
were
for care and
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placed: 18 HA-coated and 18 non-coated implants. Each animal received 6 implants: 3 HA- 
coated implants in the one femoral condyle and 3 non-coated implants in the other femoral 
condyle. Regarding the use of PRP, PRP gel was applied in two goats, PRP liquid fraction via 
dipping of the implant was applied in two other goats, while the residual two goats did not 
receive any PRP application at all (control group). This resulted in six different treatment 
groups: (1) CaP coated implants (CaP), (2) CaP coated implants + PRP liquid (CaP/ liquid),
(3) CaP coated implants + PRP gel (CaP/gel), (2) Non-coated implants (Ti), (3) Non-coated 
implants + PRP liquid (Ti/ liquid), and (6) Non-coated implants + PRP gel (Ti/gel). 
Postoperatively, the animals were housed in a stable, where they could move freely. The 
animals were sacrificed at 6 weeks after implantation by an overdose of Nembutal® and the 
implants with surrounding tissue were retrieved for histological preparation.
Histological preparation
After sacrifice of the animals, the femoral distal condyles were excised and excess tissue was 
removed. Then using a diamond saw, the retrieved condyles were divided in smaller 
specimens, suitable for histological processing. Each specimen included one implant with 
surrounding bone. The samples were fixed in 4% formaldehyde. Subsequently, they were 
dehydrated through a graded series of ethanol, embedded in methylmethacrylate (MMA) and 
finally they were polymerized. Longitudinal mid-implant thin non-decalcified sections (10 
^m) were made with a modified diamond blade sawing microtome technique. The sections 
were stained with methylene blue and basic fuchsin and examined for histological and 
histomorphometrical evaluation.
Histological and Histomorphometrical evaluation
The histological evaluation was performed with a light microscope (Leica Microsystems 
GmbH, Wetzlar, Germany) and included a description of the observed tissue response. 
Additionally, microscopic images were projected with a magnification of 1.6x on a colour 
monitor and a digital image analysis software (Leica Qwin Pro-image analysis system, 
Wetzlar, Germany) was used for the histomorphometrical measurements.
The histomorphometrical analysis consisted of:
(a) Bone contact percentage: The amount of bone contact was defined as the percentage of 
implant length at which there was direct bone-implant contact without intervening soft tissue 
layer. The measurements were performed along the whole length of the implant, excluding the 
most apical part.
(b) Bone mass percentage: The bone mass was evaluated as the percentage of bone present in 
two defined fields: 0-1 mm and 1-2 mm next to the implant surface.
All measurements were performed for at least 3 sections per implant and the results were 
based on the average of these measurements.
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Statistical analysis
All measurements were statistically evaluated using paired t-test for paired data or an analysis 
of variance (ANOVA) and Tukey test for multiple comparisons among the means of different 
groups. The method of Kolmogorov and Smirnov was used to confirm that the data were 
sampled from a Gaussian distribution. In case of using ANOVA analysis, the method of 
Bartlett tested the assumption that the standard deviations of the groups were equal. 
Differences were considered statistically significant when the P-value was less than 0.05.
3. Results
Experimental animals
None of the goats showed signs of weakness after retrieval of the blood prior to surgery. All 
goats had an uneventful post-operative recovery and their weight remained stable during the 
experimental period. At sacrifice, no clinical signs of inflammation or adverse tissue reactions 
could be seen. Radiographs, taken parallel to the long axis of the implant, assured that the 
implants were located in trabecular bone. Although three implants appeared to be placed in 
the proximity of the epiphyseal growth plate, this did not hamper their histomorphometrical 
evaluation.
PRP p reparation
The volumes of the PRP and platelet concentrations, as harvested from each goat, are shown 
in Table 1. According to this randomized study design, goat 1 and goat 4 received implants 
without application of PRP. The PRP preparation resulted in platelet concentrations ranging 
from 800 to 1200 x 106 platelets/ml.
Histological evaluation
The light microscopical evaluation of the implants showed an uneventful healing of all 
implants without any sign of inflammatory response. In all sections, the marginal bone was at 
the same level with the top of the implant. Occasionally, coronal invasion of connective tissue 
along the implant surface was observed in some sections of all six implant groups, but never 
exceeded more than 2 mm. Since the histomorphometrical measurements were performed 
along the whole length of the implant, the crestal resorption and connective tissue invasion 
affected the bone contact percentage negatively. In most sections, the drilling procedure 
appeared to be very accurate. In a limited number of the sections, the drill hole was somewhat 
oversized in terms of depth. Therefore, the most apical part (bottom) of the implants was 
excluded from the study. The damage caused by the drilling procedure appeared to be very 
limited, as characterized by the absence of drilling debris or fractured bone particles.
CaP coated implants without PRP (Fig. 2a)
The histological sections revealed for all CaP-coated implants a very uniform bone reaction.
In the interfacial area, new bone formation had occurred along the implant surface, whereas 
marrow spaces of different volume had interrupted this bone-implant contact. The bone was 
in very close contact with the cement surface, without any sign of intervening fibrous tissue 
layer. The implants were never associated with an inflammatory response.
CaP coated implants with PRP liquid (Fig. 2b)
In the area directly adjacent to the implant, new bone formation had occurred on the implant 
surface without any observation of a soft tissue layer. The surface of the implants was almost 
completely covered with a thin layer of new lamellar bone. At the implant-bone interface
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remodeling lacunas containing osteoblasts and bone marrow-like tissue were clearly visible. 
Next to the implant, no accumulations of inflammatory cells were seen.
CaP coated implants with PRP gel (Fig. 2c)
No differences in healing response between this group and the other two groups of CaP coated 
implants could be observed. A tight contact existed between the newly deposited bone and the 
CaP coated surface. In the interfacial area, new bone formation had occurred along the 
implant surface without an intervening fibrous tissue layer. Again, large marrow spaces that 
contained osteoblasts interrupted this bone-implant contact. No macrophages and giant cells 
were seen in between the implant surface and surrounding bone.
(a) (b) (c)
Figure 2: Histological sections of the CaP-coated Ti implants (magnification 16x):
(a) without application of PRP, (b) with the use of PRP liquid, (c) with the use of PRP gel.
Non-coated implants without PRP (Fig. 3a)
Also in this group, none of the non-coated Ti implants showed an adverse bone reaction. In 
the interfacial area, new bone formation had occurred along the implant surface whereas 
marrow spaces of different volume had interrupted this bone-implant contact. The new 
formed bone had mainly a lamellar structure. Similar to the other implant groups no 
inflammatory cells were seen in any section.
Non-coated implants with PRP liquid (Fig. 3b)
Bone apposition and bone remodeling lacunae with bone marrow stromal cells in close 
contact with the implant surface could be observed. The bone was closely adapted to the 
implant surface without any sign of fibrous tissue formation. The interfacial bone contact
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appeared to be more pronounced compared to the other non-coated implants. The PRP liquid 
had not evoked an inflammatory response.
Non-coated implants with PRP gel (Fig. 3c)
In almost all sections, a thin layer of new lamellar bone covered the implant surface without 
any fibrous tissue intervention. Although in some sections residual amorphous material, 
probably consisting of degraded PRP gel, occupied the intertrabecular bone voids, no 
inflammatory reaction was observed.
(a) (b) (c)
Figure 3: Histological sections of the non-coated rough Ti implants (magnification 16x): 
(a) without application of PRP, (b) with the use of PRP liquid, (c) with the use of PRP gel.
Histomorphometrical evaluation
Percentage o f bone contact: The results of the bone contact measurements are listed in Table 
2. The data show that the highest average amount of bone contact (94%) occurred for the 
CaP/liquid implants, while the Ti- implant group showed the lowest amount (60%). Statistical 
comparison of the bone contact percentages between the individual implant groups as well as 
various treatment combinations confirmed that:
1. No significant differences existed in bone contact percentage between the three CaP 
coated implant groups.
2. Ti/liquid implants showed a significantly higher bone contact percentage compared to 
the other two Ti implant groups.
3. No significant differences existed in bone contact percentage between the Ti/liquid 
and all CaP coated implant groups.
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Percentage o f bone mass: The results for the bone mass measurements are also given in Table
2. The bone mass was determined in two different zones 0-1 mm and 1-2 mm next to the 
implant surface. The results show that the percentage of bone mass in the “0-1 mm” zone 
ranged from 49% to 69%, while in the “ 1-2 mm” zone it ranged from 34% to 55%.
Statistical analysis showed that in the area 0-1 mm all the implant groups induced a similar 
bone mass except the Ti- and Ti/gel implants, which were surrounded by a significant lower 
amount of bone. Also, in the area 1-2 mm away from the implant surface, the Ti-group was 
surrounded by a lower mass of bone compared with the other groups. Finally, statistical 
evaluation (paired t-test) of the bone mass between the two zones in each group indicated that 
for the CaP-, CaP/liquid-, Ti-, and Ti/liquid-implant groups more bone mass (p<0.05) was 
present in the 0-1 zone compared to the 1-2 mm zone. Only for the implants inserted in 
combination with the PRP-gel, the amount of bone mass did not differ significantly (p>0.05) 
between the two zones.
Table 2: The mean and standard deviation of the percentage of bone contact (%) and the bone mass (%) estimated in two different zones 0-1 
mm and 1-2 mm next to the implant surface. Six separated study groups were created based on the different treatment modalities. 
Analysis of variance (ANOVA) and Tukey-Kramer multiple comparisons test were used for the statistical analysis.
Group Treatment modality Bone contact (%) Bone mass (%) 
zone 0 - 1 mm
Bone mass (%) 
zone 1 -2 mm
Ti
Ti/liquid
Ti/gel
CaP
CaP/liquid
CaP/gel
Non-coated implant + no PRP 
Non-coated implant + PRP liquid 
Non-coated implant + PRP gel 
CaP-coated implant + no PRP 
CaP -coated implant + PRP liquid 
CaP -coated implant + PRP gel
60 (± 9) * 
79 (± 11)
62 (± 1 1 ) * 
83 (± 4)
94 (± 4)
81 (± 1 0 )
55 (± 7) § 
69 (± 4)
49 (± 8 ) §
62 (± 4)
6 6  (± 7)
63 (± 9)
34 (± 1) # 
51 (± 7)
47 (± 4)
43 (± 7)
46 (± 1)
55 (± 8 )
* The statistical analysis revealed that the NC/P- and NC/Pg group had significant less bone contact than the 
rest groups (p<0.05). No other difference was significant.
§ The statistical analysis revealed that the bone density in the region of 0-1 mm next to the implant was 
significant lower in the NC/P- and NC/Pg groups as compared with all the other groups (p<0.05).
# The bone density in the region of 1-2 mm next to the implant was significant lower in the NC/P- group as 
compared only with the NC/Pl (p<0.05) and HA/ Pg groups (p<0.01).
4. Discussion
The purpose of the present study was to evaluate the effect of the surface quality (CaP-coating 
and surface roughness) in combination with the application of PRP on the initial bone 
response after implant placement.
Both non-coated and CaP-coated implants had an almost similar roughness, yet scanning 
electron microscopy revealed still small differences in surface morphology. These small 
differences were caused by the additional CaP coating. The final effect of this disparity on the 
study outcome can currently not be answered and requires further investigation. Perhaps for 
future studies, a solution for the surface roughness discrepancy can be found by deposition of 
an additional thin titanium coating on the roughened bulk titanium implant.
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Not withstanding this limitation in study design, the histological and histomorphometric 
evaluation demonstrated that the application of a thin magnetron sputtered CaP coating (1-2 
p,m thickness) favored the early bone response. After 6 weeks of implantation, a higher 
percentage of bone-implant contact was established for CaP-coated implants compared to the 
non-coated ones. These findings corroborate with previous studies with similar coated 
implants in the same animal model.9,23
Further, the results revealed that “PRP liquid” (without any activation) favored clearly the 
bone-implant contact for the roughened Ti-implants, because the PRP liquid implant groups 
always showed a significantly higher percentage of bone contact compared with the other two 
Ti-implant groups (PRP gel and control). Although there was also a tendency of an increased 
bone contact for the CaP coated implants after the application of PRP liquid, this difference 
was not statistically significant. On the other hand, no effect of the use of PRP-gel on the 
bone contact percentage was observed for both CaP-coated and non-coated Ti-implants. In a 
similar study by Zechner et al. in 2003 in a mini-pig model, the authors also failed to show 
any statistically significant effect of PRP-gel on peri-implant bone formation after a 6 week 
healing period.24 In another study, Weibrich et al. analyzed the influence of PRP-gel on bone 
regeneration around self-tapping titanium screw implants inserted in the femoral bone of 
rabbits.25 After a 4-week healing period, no advantageous effect on bone-implant contact rate 
was seen. These results are in agreement with our findings about PRP gel. An explanation for 
the difference in result between PRP-liquid and PRP-gel can be the trauma as caused during 
the installation of the PRP gel. After putting the PRP gel in place, the implant is forced into 
the implant cavity. PRP gel has a very viscous, jelly-like consistency, which can result in 
additional pressure on the drill walls of the already tightly fitting implant. As a consequence, 
the healing process at the bone-implant interface might become disturbed. Support for this 
hypothesis is found in the occurrence of degraded remnants of PRP gel in the intertrabecular 
bone voids around the Ti/gel implants. This can also clarify why Kim et al. found also a 
higher percentage of bone contact after 6 weeks of implant placement when using PRP gel, 
because they used a peri-implant defect model and not a press-fit technique for implant 
insertion.26 Additionally, it is an interesting histologic finding that remnants of PRP gel were 
only found around Ti/gel implants and not around the Ca/P implants. A possible explanation 
is that the CaP coating may play a role in the faster degradation of PRP gel. In a recent study 
27, the authors suggest that bioceramics may enhance macrophage activation.
For the bone mass measurements, the bone mass was calculated into two separated zones of 
“0-1 mm” and “1-2 mm” closed to implant surface. Changes in the former zone can be related 
to the surgical method and the materials that were used, while changes in the later zone may 
be related to the bone quality (density) of the implant preparation site. Comparison of the 
obtained data showed that the 0-1 mm zone around the Ti- and Ti/gel-implants contained 
significant less bone mass compared to the other implants. Further, the results revealed an 
increase in bone density in the “0-1 mm” zone compared with the “ 1-2 mm” zone, for all 
groups except for all the implants inserted in combination with the PRP-gel. In this case, the 
amount of bone mass did not differ significantly (p>0.05) between the two zones. An 
explanation for the difference in result obtained with PRP-gel can be again the trauma as 
caused during the installation of the gel. It is well known that bone responds to mechanical 
injury by increasing in volume and density. Slotte et al. (2003) estimated a 35% increase of 
bone mass after implant placement in comparison with control bony sites, in a rabbit model 
with a 8 week-healing period.28 Similar results were obtained in our study, since there was 
evidently an increase of bone mass in the “0-1 mm” zone next to the implant surface 
compared with the “ 1-2 mm” zone. Nevertheless, the measurements at a distance of 1-2 mm 
revealed also that the amount of bone mass was not uniform around all implant types. This 
variation in bone mass between the groups may be an indication for a difference in bone
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density between the implant preparation sites and/or experimental animals. The femoral 
condyle consists of two different sections: the epiphysis and the metaphysis, which have a 
different bone density and contain different cell populations leading to different wound 
healing events after implantation. Still, the final effect of both PRP-liquid and implant surface 
composition was consistent.
5. Conclusions
The results of the present study confirmed that magnetron sputtered Ca-P coatings can 
improve the integration of oral implants in trabecular bone. The additional use of PRP did not 
offer any significant effect on the bone response to the Ca-P coated implants, while PRP in a 
liquid form showed a significant effect on bone apposition to roughened titanium implants 
during the early post-implantation healing phase. Nevertheless, additional studies are 
necessary to elucidate the underlying phenomenon for this effect and to determine whether 
this indeed can be attributed to the PRP.
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1. Introduction
Currently, the application of oral implants is a well-accepted treatment modality to replace 
missing and lost teeth. Considering the achieved success, there is a trend to the use of 
implants in more contesting indications. For example, it has to be noticed that patients 
diagnosed with systemic diseases such as osteoporosis and diabetes compose a compromised 
area of implant therapy (Elsubeihi & Zarb 2002). Additionally, the concept of immediate 
implant loading for reducing the discomfort, inconvenience and anxiety of the patient remains 
a challenge (Gapski et al. 2003). Furthermore, clinical experience has shown that implant 
failure often occurs at relatively early stages after surgery, indicating the necessity of 
understanding the initial response of the surrounding tissues to the implant (Esposito et al. 
1998). All these above mentioned reasons justify the necessity for ongoing research to 
investigate parameters and factors that can improve oral implant osseointegration, especially 
during the early post-implantation healing phase.
Several factors such as implant design, implant surface, surgical technique, bone type and 
loading conditions have been shown to influence implant osseointegration (Joos et al. 2006). 
Also, the use of calcium phosphate (Ca-P) coatings has been shown to benefit the bone 
response during the initial healing period after implant insertion (Hayakawa et al. 2000). In 
addition to surface quality, growth factors may also stimulate bone healing around medical 
and oral implants. The effect of osteoinductive factors like Bone Morphogenetic Proteins or 
Transforming Growth Factor-P has already been a topic of various experiments (Puleo & 
Nanci 1999). Although basic clinical research has focused on the application of growth 
factors, the short shelf life and inefficient delivery to target cells are major concerns 
associated with local administration of recombinant human growth factors. The growth 
factors are expensive and high doses may be required to achieve any therapeutic effect.
An easy, cost-effective way to obtain high concentrations of growth factors for rapid wound 
healing and increased bone formation may be platelet rich plasma (PRP).
PRP is a volume of autogenous plasma with a high platelet concentration above baseline and 
a proven source of growth factors (Marx et al. 1998). In vitro, animal and human studies have 
demonstrated that the application of platelet-rich plasma (PRP) in dentistry may provide 
successful results and beneficial outcomes in tissue regeneration, bone repair and generally 
wound healing (Tozum & Demirapl 2003). The positive impact of PRP can be attributed to 
the angiogenetic, proliferative and differentiating effects on osteoblasts of Transforming 
Growth Factor-B (TGF-B) and Platelet Derived Growth Factor (PDGF), which are present in 
PRP in high concentrations (Anitua 1999). Because PRP is developed from autologous blood, 
it is inherently safe, free from transmissible diseases and has a low cost compared to 
recombinant growth factors (Marx 2004). Although, the use of PRP as a bone graft 
enhancement material has been proposed in many studies, there is a clear lack of scientific 
evidence to support the use of PRP in combination with dental implant placement (Sanchez et 
al. 2003).
Additionally, the combination of growth factors with a calcium phosphate (CaP) coating 
showed that this could facilitate the osteoinductive properties of growth factors (Vehof et al. 
2001). However, in a recent animal study in trabecular type of bone, the additional use of PRP 
gel, activated with thrombin and CaCl2 did not offer any significant effect on the bone 
response to oral implants provided with a similar Ca-P coatings as used in the earlier study 
(Nikolidakis et al. 2006). On the other hand, PRP in a liquid form (without activation) showed 
a significant effect on bone apposition to roughened titanium implants during the early post­
implantation healing phase (Nikolidakis et al. 2006). The observation that PRP liquid can 
enhance bone formation agrees with some other authors, who already questioned the necessity
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of using thrombin (Dugrillon et al. 2002, Anitua 1999). Nevertheless, more research has to be 
done to elucidate this issue.
The purpose of the present study is to investigate the effect of local application of autologous 
Platelet-rich plasma (PRP) combined with or without thrombin on the early bone healing in 
the cortical bone around oral implants with two different surface configurations, a Ca-P 
coated and a non-coated surface with similar roughness.
2. Material and methods
Implant _ preparation
Thirty-six (36) cylindrical commercially pure titanium implants with a diameter of 3.4 mm 
and length of 9 mm were used. They were grit-blasted with Al2O3 particles and then they 
were acid-etched (mixture of hydrochloric acid and sulfuric acid) for 1 minute and cleaned 
ultrasonically in isopropanol and dried at 100°C. Subsequently, half of the implants were 
provided with a thin CaP coating. The CaP coatings were applied by using a commercially 
available RF magnetron sputter deposition system (Edwards ESM 100, Sussex, UK). The 
thickness of the CaP sputter coating was 1^m, as measured using a Universal Surface Tester 
(UST, Innowep GmbH, Germany). After deposition, the coated specimens were subjected to 
an additional heat treatment (HT) for 2 hours at 550°C.
The physicochemical analysis showed that the heat-treated coatings had a crystalline apatite­
like structure with a Ca/P ratio of 1.8-2.0. Surface roughness measurements, using a Universal 
Surface Tester (UST, Innowep GmbH, Wurzburg, Germany), revealed that the roughness (Ra) 
value for the non-coated implants was 2.1 p,m, whereas the HA-coated implants showed Ra 
value of 2.3 p,m. Finally, all implants were cleaned ultrasonically for 10 minutes to remove 
any loose particles and sterilized in an autoclave.
Procedure o f PRP preparation and application
The PRP fraction was obtained from venous blood of goats one day before implant 
placement. Therefore, 250 cm3 of blood was drawn and centrifuged at a transfusion laboratory 
(SanQuin, Nijmegen, The Netherlands) in various cycles (Clemmons et al. 1983). Finally, 7.5 
ml of platelet-rich plasma suspension was obtained. Also counting of the platelet 
concentration was performed and in each batch platelet count ranged between 800 x 106/ml 
and 1200 x 106/ml.
The final application of the PRP fraction was performed via gel preparation and subsequent 
installation in the implant site, or via dipping of the implant in PRP liquid before its insertion. 
The PRP gel was obtained at the time of surgery by mixing the PRP fraction with 10% 
calcium chloride solution and 300 IU of bovine thrombin (Fibriquick®, Organon Teknika, 
Boxtel, The Netherlands). The PRP liquid was used pure without addition of any agent.
Animal model and implantation _procedure
Six healthy mature female Saanen goats, weighing about 60 kg, were used in this study.
Before surgery blood samples of the goats were taken to ensure that the animals were 
CAE/CL arthritis free. The goats were housed in the stable and national guidelines for the 
care and use of laboratory animals were observed. The surgical operation was performed 
under general anesthesia that was induced by an intravenous injection of pentobarbital and 
maintained by ethane 2-3% through a constant volume ventilator via an endotracheal tube. 
During operation, the goats were connected to a heart monitor. Also, they received antibiotic 
prophylaxis with intention to reduce perioperative infection risk according to the following 
scheme:
• During the operation: ampicillin (Albipen®) 15%, 3 ml/50 kg subcutaneously
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• 1 day after operation: ampicillin (Albipen®) LA, 7.5 ml/50 kg subcutaneously
• 3 days after operation: ampicillin (Albipen®) LA, 7.5 ml/50 kg subcutaneously 
The implants were inserted into the left and right tibial diaphysis of the goats.
For the insertion of the implants, each animal was immobilized on its back and the hind legs 
of the goats were shaved, washed and disinfected with povidone-iodine.
A longitudinal incision was made on the medial surface of the tibia and the bone was exposed 
by blunt dissection. Three pilot holes (1.6 mm) were drilled through the medial cortex and the 
medulla of the tibia. The holes were gradually widened with drills to the final diameter of the 
implants (3.4 mm) to ensure firm fixation of the implants. The distance between the holes was 
at least 2 cm. The bone preparation was performed with a very gentle surgical technique using 
a low rotational drilling speed (maximum 800 rpm) and continuous internal cooling. After 
bone preparation, the holes were irrigated with saline (NaCl 0.9%, Baxter BV, Utrecht, The 
Netherlands) and in the case of PRP group sites, the PRP was applied via: (1) gel preparation 
and subsequent installation of the gel into the implant site, or (2) dipping of the implant in 
PRP liquid fraction before its insertion. Following the press-fit insertion of the implants, the 
soft tissues were closed in separate layers using resorbable Vicryl 3-0 sutures. A total of 36 
implants were placed: 18 CaP-coated and 18 non-coated implants. A randomization scheme 
was followed for the PRP application and implant insertion. Each animal received 6 implants: 
3 CaP-coated into the one tibial diaphysis (right or left alternatively per animal) and 3 non­
coated implants into the opposite tibia. PRP fraction in a gel form was applied in goat number
3 and 6, PRP liquid via dipping of the implant was applied in goat number 2 and 5, while the 
other two goats (number 1 and 4) did not receive any PRP application. This resulted in six 
different implant groups: (1) CaP coated implants (CaP/-), (2) CaP coated implants + PRP 
liquid (CaP/ liquid), (3) CaP coated implants + PRP gel (CaP/gel), (2) Non-coated implants 
(Ti/-), (3) Non-coated implants + PRP liquid (Ti/ liquid), and (6) Non-coated implants + PRP 
gel (Ti/gel).
Postoperatively, the animals were placed under standard care. The animals were sacrificed at 
6 weeks after implantation by an overdose of Nembutal® and implants with surrounding tissue 
were retrieved for histological preparation.
Histological preparation
After sacrifice of the animals, the tibial diaphyses were excised and excess tissue was 
removed. Then using a diamond saw, the retrieved bony parts were divided in smaller 
specimens, suitable for histological processing. Each specimen included one implant with 
surrounding bone. The samples were fixed in 4% formaldehyde. Subsequently, they were 
dehydrated through a graded series of ethanol, embedded in methylmethacrylate (MMA) and 
finally they were polymerized. Longitudinal mid-implant thin non-decalcified sections (10 
^m) were made with a modified diamond blade sawing microtome technique. The sections 
were made perpendicular to the long-axis of the tibia. Finally, they were stained with 
methylene blue and basic fuchsin and examined for histological and histomorphometrical 
evaluation.
Histological and Histomorphometrical evaluation
The histological evaluation was performed with a light microscope (Leica MZ12, Leica BV, 
Rijswijk, The Netherlands) and included a description of the observed tissue response. 
Additionally, microscopic images were projected with a magnification of 25x on a colour 
monitor using a CCD/RGB camera (Sony DXC151P, Wetzlar, Germany) and digital image 
analysis software (Leica Qwin Pro-image analysis system, Wetzlar, Germany) was used for
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the histomorphometrical evaluation. During the histomorphometrical evaluation the following 
parameters (Fig. 1) were analyzed:
(a) Bone Implant Contact (BIC): The amount of bone contact was defined as the percentage of 
implant length at which there was direct bone-implant contact without intervening soft tissue 
layer. The measurements were performed along the whole length of the implant, excluding the 
apical part that was located in the medullar cavity.
(b) Bone area (BA): The bone mass was evaluated as the percentage of bone present in a 
defined field at a distance of 0 to 2 mm from the implant surface. Based on the different 
staining shading (red and brown color) two separate bone areas were distinguished, i.e. the 
New & Old Bone Area (NBA, OBA) and their percentage was calculated independently. After 
adding these two percentages and deducting their sum from the total amount a new area was 
defined: the Empty Area (EA), which was characterized from the absence of any calcified 
tissue (white color in the image).
(c) Endosteal Bone Formation Length (EBFL): The length of the new bone mass formed in 
the medullar cavity in contact with the implant surface was calculated in mm.
All measurements were performed for at least 3 sections per implant and the results were 
based on the average of these measurements.
Figure 1: A schematic drawing that illustrates the histomorphometrical parameters that were evaluated.
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Statistical analysis
All measurements were statistically evaluated by an experienced statistician using mixed 
models analysis of variance (Proc Mixed in SAS V8.1, SAS Institute Inc., Cary, NC, USA). 
This multivariate analysis based on procedures examined the correlated data and analyzed the 
random effects and the contrast between the groups. Differences were considered statistically 
significant when the P-value was less than 0.05.
3. Results
Experimental animals
None of the goats showed signs of weakness after retrieval of the blood prior to surgery. All 
goats had an uneventful post-operative recovery and their weight remained stable during the 
experimental period. At sacrifice, no clinical signs of inflammation or adverse tissue reactions 
could be seen. Radiographs taken parallel to the long axis of the implant, confirmed that all 
implants were located in the cortical bone.
Histological evaluation
The histological evaluation showed an uneventful healing of all implants without any sign of 
inflammatory response. In all sections, the marginal bone was at the same level with the top 
of the implant. Crestal invasion of connective tissue along the implant surface was observed 
in some sections of all six implant groups, but never exceeded more than 0.5 mm as a mean 
value. Since the histomorphometrical measurements were performed along the whole length 
of the implant that was placed in cortical bone, the crestal resorption and connective tissue 
invasion affected the bone implant contact percentage negatively. Sections showed also that 
the drilling procedure was very accurate. Furthermore, the damage caused by the drilling 
procedure was very limited, as characterized by the absence of drilling debris or fractured 
bone particles.
CaP coated implants without PRP (Fig. 2a)
Examination of the histological sections revealed a very uniform bone reaction for all CaP- 
coated implants. The bone was in very close contact with the CaP surface, without any sign of 
intervening fibrous tissue layer. A high bone implant contact was evident. Nevertheless, in the 
interfacial area, minimal new bone formation had occurred along the implant surface whereas 
occasionally marrow spaces of small volume had interrupted this bone-implant contact. New 
bone formation occurred mainly in the medullar cavity, where it originated from the endosteal 
bone surface and was in close contact with the implant surface. The implant part that 
penetrated into the medullary cavity did not evoke any inflammatory response.
CaP coated implants with PRP liquid (Fig. 2b)
In the area directly adjacent to the implant, new bone formation had occurred along the 
implant surface without any observation of a soft tissue layer. Again, a high bone implant 
contact was evident. Also a few remodeling lacunae in the region closed to implant surface 
were clearly visible. Furthermore, in the medullar cavity, new endosteal bone formation in 
close contact with the implant surface was observed. Next to the medullary part of the 
implant, no accumulations of inflammatory cells were detectable.
CaP coated implants with PRP gel (Fig. 2c)
Compared to the other two groups of CaP coated implants larger zones of bone remodeling 
could be observed in the area close to the implant surface. In the interfacial area, new bone 
formation had occurred along the implant surface without an intervening fibrous tissue layer.
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However, less interfacial bone contact was noticed compared to CaP groups. Further, an 
increased amount of new bone in the medullar cavity was observed. Again no inflammatory 
response was seen in the medullary cavity.
(c)
Figure 2: Histological sections of the CaP-coated Ti implants (magnification 16x): (a) without application of PRP, 
(b) with the use of PRP liquid, (c) with the use of PRP gel. Note the presence of remodeling lacunae ad resorption 
cavities (arrowheads) that are predominant in the case of PRP gel.
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Non-coated implants without PRP (Fig. 3a)
Also in this group, none of implants showed an adverse bone reaction and no inflammatory 
cells were seen in any section. In the interfacial area, new bone formation had occurred along 
the implant surface, whereas remodeling lacunae of small volume had interrupted this bone- 
implant contact. Bone-implant contact appeared to be less compared with the CaP coated 
implants. New bone formation originated from the endosteal bone surface, which was similar 
to the other implant groups.
Non-coated implants with PRP liquid (Fig. 3b)
Bone apposition in close contact with the implant surface could be observed. The bone was 
closely adapted to the implant surface without any sign of fibrous tissue formation. The 
interfacial bone contact appeared to be more pronounced compared to the other non-coated 
implants. A minimal remodeling pattern was noticeable in the cortical bone close to the 
implant. Moreover, bone formation extended from the endosteal bone surface into the 
medullar cavity. The PRP liquid did not evoke an inflammatory response.
Non-coated implants with PRP gel (Fig. 3c)
In almost all sections, new bone covered the implant surface without any fibrous tissue 
intervention. Compared to the other two groups of non-coated implants larger zones of bone 
remodeling could be observed close to the implant, which had a negative effect on the amount 
of bone-implant contact. A similar amount of new bone had formed into the medullar cavity 
compared with the other non-coated implants. Again, no inflammatory reaction was observed.
Histomorphometrical evaluation
All the results of the histomorphometric measurements are listed in Table 1.
Bone Implant Contact (BIC): The data indicated that the highest average amount of bone 
contact (87%) occurred for the CaP/- implants, while the Ti/gel implant group showed the 
lowest amount (57%). Statistical comparison of the bone contact percentages between the 
individual implant groups as various treatment combinations confirmed that:
4. No significant differences existed in bone contact percentage between the three CaP 
coated implant groups.
5. No significant differences existed in bone contact percentage between the three Ti 
non-coated implant groups. However, Ti/liquid group revealed a tendency (10-22%) 
for higher amount of bone contact compared to the other two non-coated groups.
6. Non-coated implants showed lower bone contact percentages compared to the three 
CaP coated implant groups. The difference between CaP/- and Ti/- or Ti/gel 
approached a significant level (Fig. 4).
Bone area (BA): The bone area was determined as the percentage of bone present in a defined 
field from 0 to 2 mm near to the implant surface and based on the different staining shading 
three separate areas were evaluated independently, the New Bone Area (NBA), the Old Bone 
Area (OBA) and Empty Area (EA). The results did not indicate any statistical significant 
difference between the different groups in each evaluated bone area. However, the two PRP 
gel groups (Ti/gel and CaP/gel) revealed a tendency for higher values regarding the EA. 
Endosteal Bone Formation Length (EBFL): The combination of CaP coated implants and 
PRP gel (CaP/gel) showed a significant higher value of EBFL (2.6 mm) compared to all the 
other groups.
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(c)
Figure 3: Histological sections of the non-coated rough Ti implants (magnification 16x): (a) without application of PRP, 
(b) with the use of PRP liquid, (c) with the use of PRP gel. Note the presence of remodeling lacunae and resorption cavities 
(arrowheads) that are predominant in the case of PRP gel.
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Table 1: The mean and standard deviation of bone contact (%), old bone area (%), new bone area (%), 
empty area (%) and endosteal bone formation length (mm) in each study group.
Group Treatment modality BIC (%) OBA (%) NBA (%) EA (%) EBFL (mm)
Ti/- Non-coated implant + no PRP 69 (±14) * 84 (± 6) 12 (± 6) 4 (± 3) 1.5 ( ± 0.6)
Ti/liquid Non-coated implant + PRP liquid 79 (± 8) 79 (± 7) 14 (± 5) 7 (± 6) 1.5 (± 0.8)
Ti/gel Non-coated implant + PRP gel 57 (±15) * 72 (± 8) 14 (± 5) 14 (± 6) § 1.7 (± 0.7)
CaP/- CaP-coated implant + no PRP 87 (± 8) * 85 (± 5) 9 (± 3) 6 (± 4) 1.6 (± 1.1)
CaP/liquid CaP -coated implant + PRP liquid 84 (± 8) 82 (± 8) 13 (± 6) 5 (± 3) 1.8 (± 0.8)
CaP/gel CaP -coated implant + PRP gel 81 (±10) 77 (± 9) 12 (± 5) 11 (±10) § 2.6 (± 0.9) #
* CaP/- group showed a significant higher value of BIC compared to Ti/- and Ti/gel group (p<0.05) 
§ Ti/gel and CaP/gel showed a significant higher value of EBA compared to th  other groups (p<0.05) 
# CaP/gel group showed a significant higher value of EBFL compared to the other groups (p<0.05)
BIC: Bone Implant Contact, OBA: Old Bone Area, NBA: New Bone Area, EBA: Empty Area,
EBFL: Endosteal Bone Formation Area
4. Discussion
The purpose of the present study was to evaluate the effect of the application of PRP on the 
early cortical bone response after placement of implants with two different surface 
configurations. Both non-coated and CaP-coated implants were used, which had an almost 
similar surface roughness. The final application of the PRP fraction was done via gel 
preparation and subsequent installation of the gel into the implant site, or via dipping of the 
implant in PRP liquid before its insertion.
The histological and histomorphometric evaluation demonstrated that after 6 weeks of 
implantation, a higher percentage of bone-implant contact was established for CaP-coated 
implants compared to the non-coated ones. Similar results have been obtained in animal 
studies in trabecular bone (Hayakawa et al. 2000, Nikolidakis et al. 2006).
Regarding the application of PRP, no effect of the use of PRP-gel on the bone-implant contact 
percentage was observed for both CaP-coated and non-coated Ti-implants. These results 
corroborate with our previous study (Nikolidakis et al. 2006) in which a similar study design 
was used but where the implants were placed in trabecular bone (femoral condyle). The 
results are also in agreement with studies of other researchers. For example, Zechner et al.
(2003) failed to show any statistically significant effect of PRP-gel on peri-implant bone 
formation in a mini-pig model (mandible) after a 6 week healing period. Also, Weibrich et al.
(2004) analyzed the influence of PRP-gel on bone regeneration around self-tapping titanium 
screw implants inserted in the femoral bone of rabbits. After a 4-week healing period, no 
advantageous effect on bone-implant contact rate was seen.
On the other hand, “PRP liquid” (without any activation) revealed a tendency to favor the 
bone-implant contact for the roughened Ti-implants. A similar result was obtained in our 
previous study (Nikolidakis et al. 2006) with the same design in trabecular bone, but now the 
beneficial difference (10%) did not reach a statistically significant level. No additional 
beneficial effect of the application of PRP liquid was seen for the CaP coated implants.
As postulated for our trabecular bone study (Nikolidakis 2006), an explanation for the 
difference in result between PRP-liquid and PRP-gel can be the mechanical trauma as caused 
by the pressure after application of the PRP gel. After putting the PRP gel in place, the 
implant is forced into the implant cavity. PRP gel has a very viscous, jelly-like consistency,
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(a) (b)
Figure 4: Histological section of (a) CaP-coated Ti implant without application of PRP and (b) non-coated rough Ti implants 
with the use of PRP gel (magnification 25x). CaP coated implants without PRP showed significantly higher bone contact percentages. 
Note also the presence of remodeling lacunae and resorption cavities in the case of PRP gel.
which can result in additional pressure on the drill walls of the already tightly fitting implant. 
As a consequence, the healing process at the bone-implant interface includes an extensive 
resorption phase due to pressure and necrosis of interfacial bone. The current 
histomorphometrical data concerning the Empty Area may support this hypothesis. Both PRP 
gel groups (CaP/gel and Ti/gel) reported higher values regarding the presence of empty 
spaces, which represents remodeling lacunae and resorption cavities, at 0-2 mm distance from 
implant surface.
This can also clarify why Kim et al. (2002) found also a higher percentage of bone contact 
after 6 weeks of implant placement when using PRP gel, because they used a peri-implant 
defect model and not a press-fit technique for implant insertion. Additionally, these results 
may indicate that the concentrated platelets in PRP do not absolutely require exogenous 
thrombin for releasing growth factors and stimulating cells. Some authors have already 
questioned the necessity of using thrombin for PRP preparation and application (Dugrillon et 
al. 2002, Anitua 1999).
Analyzing the measurements of the bone mass parameters, New & Old Bone Area (NBA, 
OBA), no difference was observed between the groups. All groups revealed similar 
percentages of old and new bone and no difference could be found in the remodeling pattern 
regarding the application of the PRP at this early post-implantation healing period in cortical 
bone. It has been suggested that PRP may interfere with the osteoblastic activity via the 
growth factors that are included in PRP (Marx 2004). If this is indeed true, then a dissimilar 
distribution of the percentage of old and new bone among the groups would be expected. In 
case for example that PRP could stimulate osteoblasts, more new bone mass should be 
observed in the PRP groups. The results of the present study do not support this suggestion. 
Further, new bone formation was evident into the medullar cavity for all groups. The new 
bone mass originated from the endosteal surface of the diaphysial cortical bone and was in 
contact with the implant surface. It is remarkable that the group with the combined treatment 
modality, CaP coated implants with PRP gel (CaP/gel), reached a statistical significant higher 
value (EBFL: 2.6 mm) compared to the other groups. This observation indicates indeed a 
regenerative potential of PRP gel. The conditions of the medullar cavity are different from the
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cortical bone-implant interface considering different cell populations and stress application. 
This difference explains also the contradictory behavior of PRP gel in the cortical region. 
Also, we have to emphasize that the combination of growth factors, as present in PRP, with 
calcium phosphate ceramics may enhance the osteoinductive properties of growth factors (Le 
Guehennec et al. 2004). CaP ceramics are known to have a high affinity for growth factors 
(Vehof et al 2001). This can explain the significant higher value of the group with the 
combined treatment modality, i.e. CaP coated implants with PRP gel (CaP/gel).
5. Conclusions
The results of the present study confirmed that magnetron sputtered Ca-P coatings can 
improve the integration of oral implants in cortical bone. The additional use of PRP did not 
offer any significant effect on the cortical bone response to the Ca-P coated implants, while 
PRP in a liquid form showed an effect on bone apposition to roughened titanium implants 
during the early post-implantation healing phase. Nevertheless, additional studies are 
necessary to elucidate the underlying phenomenon for this effect and to determine whether 
this indeed can be attributed to the PRP.
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1. Introduction
The application of oral implants has been considered as a well-accepted treatment modality to 
replace missing and lost teeth [1]. However, there is skepticism about the use of implants in 
more demanding situations. For example, patients diagnosed with systemic diseases such as 
osteoporosis and diabetes are considered as a compromised indication for implant therapy [2]. 
Additionally, the concept of immediate implant loading to reduce the discomfort, 
inconvenience, and anxiety of the patient remains a challenge [3]. Furthermore, clinical 
experience has shown that implant failure often occurs at relatively early stages after surgery, 
which indicates the need to improve the initial response of the surrounding tissues to the 
implant [4]. All these above-mentioned reasons justify the necessity for ongoing research to 
investigate the parameters that can evoke an enhanced implant-bone response during the early 
post-implantation healing phase, as characterized by the presence of increased bone-to- 
implant contact and bone amount in close vicinity of the implant.
Several factors such as implant design, implant surface, surgical technique, bone type and 
loading conditions have already been shown to influence implant-bone response [5]. In 
addition, the functionality of the implant surface by the deposition of bioactive signaling 
molecules, like growth factors, may also influence bone healing around oral implants [6]. 
Transforming Growth Factor -P, Bone Morphogenetic Proteins, Platelet-derived Growth 
Factor, and Insulin-like Growth Factor have been reported to have an effect on bone healing
[7].
Transforming Growth Factor-p (TGF -P) has been referred as member of a super-family of 
growth and differentiation factors including also the bone morphogenetic proteins [8]. TGF-P 
has been reported to promote extracellular matrix production, to enhance the 
proliferative activity of periodontal ligament fibroblasts, and to stimulate biosynthesis of 
collagen type I and fibronectin [9]. TGF-P has been also observed in bone cultures and it is 
supposed that its primary role in bone formation is to induce deposition of bone matrix and to 
increase the pool of committed osteoblasts [7]. TGF -p  has three different isoforms of which 
TGF-P1 is known to play a major role in bone formation, while TGF-P2 and TGF-P3 are 
supposed to be of minor importance regarding bone healing [10]. The ability of TGF-P1 to 
enhance bone healing has already been demonstrated in various animal studies [11-16]. Also, 
the osteogenic potential of TGF-P 1 applied in combination with implant placement has been 
confirmed [17-21]. However, very high or repeated doses of the growth factor and 
supplementary carrier materials were used to achieve a favorable effect, which makes the 
application TGF-P 1 for implant therapy an expensive and complicated approach.
In view of the above mentioned, it is challenging to explore the concept of a single, low dose 
of TGF-P 1 loaded on implant surface to improve implant fixation. Therefore, aim of the 
present study is to investigate the effect of transforming growth factor P1 (TGF-P1), applied 
on the implant surface in two different low concentrations (0.5 and 1.0 |ig), on the early bone 
healing around oral implants placed in trabecular bone.
2. Materials & Methods
2.1 Implant preparation
Twenty-four cylindrical screw type implants provided with an acid-etched rough surface 
(Dyna Helix® Implant System, Dyna Dental Engineering BV, Bergen op Zoom, Netherlands) 
were used. The implants measured 4 mm in diameter and had a length of 8 mm. All implants 
were cleaned ultrasonically in isopropanol and sterilized in an autoclave.
For growth factor loading, recombinant human TGF-P 1 (R&D Systems, Minneapolis, USA) 
was dissolved in sterile 4 mM HCl containing 1 mg/ml bovine serum albumin (BSA; Sigma
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Aldrich, Zwijndrecht, the Netherlands). Administration was achieved by direct adsorption of 
the growth factor on the implant surface. Aseptic conditions were maintained throughout the 
adsorption process. A volume of 10 ^l of the HCl/BSA solution (containing either 1.0 ^g or 
0.5 ^g TGF-P1) was applied with a pipette at the implant surface.
In total three groups were created:
(a) 8 unloaded Ti implants (Ti) served as control
(b) 8 Ti implants loaded with 1.0 |ig TGF-P 1 (Ti-TGF10)
(c) 8 Ti implants loaded with 0.5 |ig TGF-P1 (Ti-TGF05)
After loading, implants were immediately stored at - 80°C for one hour, and placed in a 24- 
wells plate for overnight lyophilisation.
2.2 In vitro rhTGF- ftl release assessment
For measuring the amount and kinetics of TGF-P1 released from the implant surface, an in 
vitro release assay was performed in culture medium. A sterile buffer solution containing 100 
ng of human recombinant TGF-P1 (R&D Systems, Minneapolis, USA) was applied with a 
pipette onto five titanium disks, which had an acid etched surface similar to the used implants. 
The substrates were then placed in polypropylene tubes with 2 mL of modified Eagle’s 
medium (a-MEM; GIBCO-BRL, Life Technologies, Breda, Netherlands). Incubation was 
performed on a shaker at 37°C. At the time points of 15 min, 30 min, 1 h, 2 h, 4 h and 24 h, 
100 jul of the medium from each tube was aspirated and 100 ¡ul of fresh a-MEM solution was 
added to fill up the total volume. Thereafter, the amount of TGF-P 1 in the aspirated samples 
was measured with the use of a TGF-P 1-specific enzyme-linked immunosorbent assay 
(Quantikine ELISA kit, R&D Systems, Abingdon, UK) according to the manufacturer’s 
instructions. A negative control medium without additives was also used. The amount of 
TGF-P 1 was determined by measuring the absorbance at 450 nm, using a 96-well/microplate 
reader (EL 800 universal microplate reader; Bio-Tek Instruments, Winooski, VT, USA).
2.3 Animal model and implantation procedure
Eight healthy mature female Saanen goats, weighing about 60 kg, were used in this study. The 
research protocol was approved by the university animal ethics committee (UMCN-DEC 
2007/145). Before surgery, blood samples of the goats were taken to ensure that the animals 
were CAE/CL arthritis free. The goats were housed in a stable and national guidelines for the 
care and use of laboratory animals were applied. The surgical operation was performed under 
general anesthesia that was induced by an intravenous injection of pentobarbital and 
maintained by ethane 2-3% through a constant volume ventilator via an endotracheal tube. 
During operation, the goats were connected to a heart monitor. Also, they received antibiotic 
prophylaxis to reduce the perioperative infection risk according to the following scheme:
• During the operation: ampicillin (Albipen®, Intervet BV, Boxmeer, Netherlands) 3 ml/50 
kg subcutaneously
• 1 day after operation: ampicillin (Albipen®, Intervet BV, Boxmeer, Netherlands) 7.5 ml/50 
kg subcutaneously
• 3 days after operation: ampicillin (Albipen®, Intervet BV, Boxmeer, Netherlands) 7.5 
ml/50 kg subcutaneously
The implants were inserted into the left distal femoral condyle of the goats.
For the insertion of the implants, each animal was immobilized on its back and the hind legs 
of the goats were shaved, washed and disinfected with povidone-iodine.
A longitudinal incision was made on the medial side of the femur and the bone surface was 
exposed. Three pilot cavities (1.6 x 8.0 mm) were drilled, which were gradually widened with 
drills to the final diameter of the implants (4 mm) to ensure firm initial fixation of the 
implants. The distance between the holes was at least 2 cm. The bone preparation was
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performed with a very gentle surgical technique using a low rotational drilling speed (maxi­
mum 800 rpm) and continuous internal cooling. After bone preparation, the implant sites were 
irrigated with saline (NaCl 0.9%, Baxter BV, Utrecht, The Netherlands) and the implants 
were installed. Each animal received 3 implants: one Ti, one Ti-TGF05 and one Ti-TGF10. A 
randomization scheme (by using a computer-generated randomization software; 
http://www.randomizer.org/) was used for implant placement to ensure similar bone 
conditions for all implants. Following insertion of the implants, the soft tissues were closed in 
separate layers using resorbable Vicryl 3-0 sutures.
Postoperatively, the animals were placed under standard care. The animals were sacrificed at 
6 weeks after implantation by an overdose of pentobarbital (Nembutal®, Apharmo, Arnhem, 
Netherlands) and implants with surrounding tissue were retrieved for histological preparation.
2.4 Histological preparation
After sacrifice of the animals, the femoral condyles were excised and excess tissue was 
removed. Then using a diamond saw, the retrieved bone parts were divided in smaller 
specimens, suitable for histological processing. Each specimen included one implant with 
surrounding bone. The samples were fixed in 4% formaldehyde. Subsequently, they were 
dehydrated through a graded series of ethanol, embedded in methylmethacrylate (MMA) and 
finally they were polymerized. Longitudinal mid-implant thin non-decalcified sections (10-20 
^m) were made with a modified diamond blade sawing microtome technique. Finally, they 
were stained with methylene blue and basic fuchsin and examined for histological and 
histomorphometrical evaluation.
2.5 Histological and Histomorphometrical evaluation
The histological evaluation was performed with a light microscope (Leica MZ12, Leica BV, 
Rijswijk, The Netherlands) and included a description of the observed tissue response. 
Additionally, microscopic images were projected with a magnification of 25x on a color 
monitor using a CCD/RGB camera (Sony DXC151P, Wetzlar, Germany) and digital image 
analysis software (Leica Qwin Pro-image analysis system, Wetzlar, Germany) was used for 
the histomorphometrical evaluation, which included the following analysis:
a) Bone Implant Contact (BIC): The amount of bone contact was defined as the percentage of 
implant length at which there was direct bone-implant contact without intervening soft 
tissue layer.
b) Bone mass (BM): The bone mass was evaluated as the percentage of bone present in two 
defined fields, along the implant length, at a distance of 0-1 mm (area within the implant 
threads) and 1-2 mm (area outside the implant threads) from the implant surface.
All measurements were performed for at least three sections per implant and the results were 
based on the average of these measurements.
2.6 Statistical analysis
All measurements were statistically evaluated by an experienced statistician using commercial 
available software ((Instat® 2000, version 3.05, GraphPad Software Inc., San Diego, USA). 
The method of Kolmogorov and Smirnov was used to confirm that the data were sampled 
from a Gaussian distribution. Repeated measures ANOVA were applied to analyze data and 
Tukey’s post hoc test was used for the multiple comparisons among the three groups. 
Differences were considered statistically significant when the P-value was less than 0.05.
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3. Results
3.1 In vitro rhTGF-^1 release
The in vitro release profile of TGF-P1 from the titanium surface was determined up to 24 h 
(Fig. 1). A burst-like release of the growth factor was observed. After 30 min, about100% of 
the loaded growth factor had been released into the medium from the titanium surface.
Fig. 1 The in vitro release profile of TGF-p1 from the titanium surface determined within 24 hours.
3.2 Experimental animals
All goats had an uneventful post-operative recovery and their weight remained stable during 
the experimental period. At sacrifice, no clinical sign of inflammation or adverse tissue 
reaction was seen. Radiographs taken perpendicular to the long axis of the implant, confirmed 
that all implants were surrounded by trabecular bone.
3.3 Histological evaluation
The histological evaluation showed an uneventful healing of all implants without any sign of 
inflammatory response. Sections showed also that the drilling procedure was very accurate. 
Furthermore, the damage caused by the drilling procedure was very limited, as characterized 
by the absence of drilling debris or fractured bone particles.
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Ti implants (Fig. 2)
Examination of the histological sections revealed a very uniform bone reaction for all Ti 
implants. The bone was in very close contact with the implant surface, without any sign of an 
intervening fibrous tissue layer. A high bone-to-implant contact was evident, whereas 
occasionally marrow spaces interrupted this bone-implant interface. Most of the specimens (5 
out of 8) revealed crestal bone resorption (mean value: 0.2 mm).
Fig. 2 Representative histological section of a Ti implant (control group) 
placed in trabecular bone of femoral condyle (magnification 25x).
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Ti-TGFo 5 implants (Fig. 3)
In the area directly adjacent to the implant, new bone formation had occurred along the 
implant surface. A moderate bone-to-implant contact was apparent. In the interfacial area, 
new bone formation with lamellar structure had occurred along the implant surface, whereas 
marrow spaces of different volume interrupted the bone implant interface. However, the 
presence of a soft tissue layer in contact with implant surface was also evident in four 
samples. Only three specimens demonstrated crestal bone resorption (mean value: 0.3 mm).
Fig. 3 Representative histological section of Ti-TGFo.5 implant (Ti implants loaded 
with 0.5 g^ TGF-p1) placed in trabecular bone of femoral condyle (magnification 25x).
76
Ti-TGFi 0 implants (Fig. 4)
Similarly to both other groups, new bone formation had occurred along the implant surface. 
Additionally in five out of eight implants, bone formation was interrupted with an intervening 
fibrous tissue layer covering less than 50% of implant surface (Fig. 5). Clearly, less interfacial 
bone contact was noticed compared to other groups. Most of the specimens did not 
demonstrate any crestal bone resorption (mean value: 0.1 mm).
Fig. 4 Histological section of Ti-TGFx.0 implant (Ti implants loaded with 1.0 g^ TGF-p1) 
placed in trabecular bone of femoral condyle (magnification 25x).
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Fig. 5 New bone formation along the implant surface was interrupted from fibrous 
tissue layer in five out of the eight Ti-TGF1.0 implants (magnification 100x).
3.4 Histomorphometrical evaluation
All the results of the histomorphometrical measurements are listed in Table 1.
a) Bone Implant Contact (BIC): The Ti implants demonstrated the highest percentage of bone 
contact (65 ± 4 %), while Ti-TGF10 implants showed the lowest amount (45 ± 12 %). The 
difference between these two groups (Ti vs. Ti-TGF10) was statistically significant (p < 
0.05).
b) Bone mass (BM): The bone mass at the distance 1-2 mm from implant surface ranged from 
58-61 % (as a mean value) among the groups indicating similar bone density for all 
preparation sites. In the region next to implant surface 0-1 mm (inter-threads area) new 
bone formation was evident in all three groups resulting in an increase of the total amount 
of bone mass in this zone (range: 65-68%). No statistically significant differences were 
observed between the groups.
Table 1: The mean and standard deviation of the percentage of bone implant contact (BIC) and the bone mass (BM) estimated in two 
different zones 0-1 mm and 1-2 mm from the implant surface. Repeated measures analysis of variance (ANOVA) and Tukey-Kramer 
multiple comparisons test were used for the statistical analysis.
Group
Ti
T1-TGF0.5
T1-TGF1.0
BIC (%
56 (± 4) * 
48 (± 7)
45 (± 12) *
BA 
zone 0-1 mm
68 (± 5)
65 (± 7)
66 (± 6)
BA 
zone 1-2 mm
60 (± 8)
58 (± 12)
61 (± 11)
P value
* (p<0.05)
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4. Discussion
The purpose of the present study was to evaluate the efficacy of TGF-P 1 on the early bone 
healing of oral implants placed in the trabecular bone (femoral condyle) of an animal model. 
Two different concentrations of TGF-P 1 were applied to commercially available oral 
implants; a low dose of 0.5 |ig (Ti-TGF05) and a higher dose of 1.0 |ig (Ti-TGF10). 
Additionally, unloaded implants (Ti) without growth factor application were used and served 
as control group. The results showed that the TGF-P1 loaded Ti implants were not superior to 
the unloaded implants considering the bone healing response.
The application of growth factors for bone regeneration is an expensive approach and only 
very low doses can be afforded for implant therapy regarding the cost/benefit ratio. In 
addition, high concentrations of growth factors are related to tissue toxicity and the clinical 
efficacy of a high dosage is questioned [22]. In view of this, it has to be noticed that the 
efficacy of TGF-P1 to support implant healing by increasing significantly the bone formation 
around implants, compared to control group, has already been demonstrated in several animal 
studies not only after application of the growth factor in high amounts (10 -335 p,g)
[16,19,21], but also in low amounts (0.3-1.0 p,g) [14,15,18,20]. Nevertheless, the results of the 
current study do not corroborate with these previous studies. An explanation for this 
discrepancy in results can be the study design, as all these studies had a different study design 
compared to the present study. Most of them used an impaired bone healing model (gap 
healing model) by creating a gap of 1 to 3 mm between bone host site and implant [14­
16,18,20] and TGF-P1 was not loaded directly on the implant surface, but a separate carrier 
material was used [14-16, 18-21]. In the current study, the TGF-P1 was loaded via adsorption 
on the implant surface to simplify the process compared to the use of a carrier material (i.e. 
encapsulation of the bioactive agent in biodegradable coatings). The use of carriers can 
increase additionally the therapeutic cost and may interfere with the implant fixation.
Further, it has to be emphasized that in contrast to the favorable reports, several studies have 
also described the inability of TGF-P1 to promote bone healing [23-25]. For example in the 
study of Aspenberg et al.[23], forty-four rats received titanium bone chambers in their 
proximal tibiae. All chambers were provided with cylinders of porous hydroxyapatite that 
were treated with 1, 33, or 1000 ng of TGF P1 and compared with untreated contralateral 
control implants. After six weeks of implantation, the growth factor loaded chambers showed 
an inhibition for bone ingrowth and there was a negative correlation between TGF P1dose and 
bone formation. The authors based the explanation for their negative results on the ambiguous 
role of TGF-P1, which can stimulate also a fibrotic reaction. A similar observation was done 
by Tielinen et al. [24], who inserted bioabsorbable implants containing 50 |ig of TGF-P1 in 
the rat distal femur. After three weeks of implantation, the histological analysis demonstrated 
fibroblast-rich mesenchymal tissue inside the defects treated with TGF-P1. The researchers 
supported their findings on the broad range of activities of this growth factor. Finally, Ueda 
and coworkers [25] demonstrated that a single dose of 0.1 |ig TGF-P1was ineffective to 
enhance bone formation in skull defects in rabbits after 6 weeks. The fast diffusion of the 
growth factor was claimed as a possible explanation.
In the current study, an important finding was that many of the implants loaded with the 
growth factor demonstrated a fibrous tissue layer in close contact with the implant surface. 
Transforming growth factor-P (TGF-P) is a ubiquitous peptide that is expressed by nearly all 
cell types and is known to regulate an extensive array of cellular processes, including 
proliferation, differentiation, extracellular matrix elaboration, hematopoeisis, angiogenesis, 
immune responses and cell death [26]. TGF-P 1 was selected in this study as it is known to 
play a role in the rate of new bone formation, while TGF-P2 and TGF-P3 are supposed to be 
of minor importance regarding bone regeneration [10]. However, several studies have
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questioned the TGF-P 1 efficacy on bone formation. TGF- P1 has been shown to be an inducer 
of osteoblasts proliferation, but also to be an inhibitor of alkaline phosphatase activity and 
osteoblast mineralization [27]. Further, TGF-P 1 does not only regulate the proliferation of 
cells specific to the skeleton, but also shows a broad range of activities such as stimulator of 
fibroblasts [28]. This occurrence of fibrous tissue instead of bone formation after TGF-P1 
application has already been noticed by other authors [29-31].
To elaborate further on this conflicting behavior of TGF-P, the bone healing process around 
implants has to be considered. During the drilling of the implant bed, blood vessels are 
damaged, which results in hemorrhage and blood clot formation. Subsequently, the wound 
healing process is initiated with a primary inflammatory phase, which lasts from 30 minutes 
to one day [32]. During this phase, inflammatory and blood cells can be detected at the bone- 
implant interface and their activation leads to a release of growth factors. All these factors 
play an important role in the regulation of the wound-healing cascade and among them TGF-P 
has been shown to be of considerable importance [33]. In this early stage, TGF-P as released 
from blood platelets and leukocytes can induce in the damaged bone tissue the production of 
extracellular matrix components including fibronectin, collagen and proteoglycans, whereas it 
is also a mitogenic and chemotactic factor for fibroblasts. The TGF-P activity is terminated 
when extracellular matrix production is completed [29]. Thereafter, the major event is the 
deposition of a non-collagenous matrix layer on the implant surface by osteogenic cells, 
which finally mineralizes. The interaction of red blood cells, fibrin, and platelets with the 
implant surface may modulate the migration, differentiation, and activity of osteogenic cells 
during peri-implant healing [33]. It is supposed that osteoblasts attach on the implant surface 
one day after implant insertion [34]. Then, TGF-P has a different role and may accelerate 
bone formation by inducing osteoblasts proliferation and migration to the wound area [35]. 
Therefore, failure to regulate TGF-P production during the early inflammatory phase results 
in accelerated extracellular matrix production, which finally causes fibrotic tissue formation 
[29,30]. It can be assumed that exogenous local administration of TGF-P1 immediately after 
injury during the inflammatory phase may provoke a fibrotic tissue formation instead of 
osteogenesis. In the present study, TGF-P1was delivered from the implant surface into the 
wound bed very early in a burst release pattern, which provides an explanation for the 
obtained negative results. Thus, single dose applications of TGF-P1 may not promote bone 
healing and the enhancement of bone regeneration may be dependent on a delayed release 
pattern [28].
Finally, lack of difference in bone formation between test and control group at some distance 
from the implant surface was also observed. The growth factor that released immediately 
seems to have a very restricted local effect on bone formation. This observation is in 
agreement with other reports which also describe the local effect of growth factors [12, 17,
18]. Further, crestal resorption was noticed in some specimens. This phenomenon can be 
attributed to the surgical procedure due to the elevation of the periosteum and the stress 
applied by the implant in the cortical area [36].
5. Conclusions
Within the limitations of this study, it can be concluded that a burst released low dose of 
TGF-P 1 has a negative influence on the integration of oral implants in trabecular bone during 
the early post-implantation healing phase. Therefore, the application of a low dose of TGF-P 1 
on an oral implant surface, which is subsequently delivered by burst release, cannot be 
recommended for clinical application.
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1. Introduction
The successful placement of dental implants in the edentulous posterior maxilla can be 
compromised by the lack of adequate alveolar bone present between the alveolar crest and the 
floor of the maxillary sinus.1 A minimum of 10 mm of vertical bone height is usually 
required for predictable implant success.2 Maxillary sinus floor elevation surgery, initially 
described by Boyne & James3, was developed to increase the height of bone available for 
implant placement in the posterior maxilla. The efficacy and predictability of this procedure 
have been demonstrated.4
The basic surgical approach involves an osteotomy performed on the lateral maxillary wall, 
elevation of the sinus membrane, and placement of bone graft material. The graft material can 
be categorized into 4 groups: autograft, allograft, xenograft, or alloplast. These graft materials 
can be used alone or in combination with each other. Tong et al.5 compared success rates of 
implants placed in sinuses grafted with different materials, and concluded that autogenous 
bone graft should be considered as the gold standard for bone replacement. However, the 
harvesting procedure of autogenous bone graft leads to morbidity at the donor site and 
prolonged operation time. Therefore, there is ongoing research to identify efficacious bone 
substitute materials. Nevertheless, despite extensive efforts, there is a lack of clarity regarding 
the bone formation supporting properties of synthetic bone substitutes.
Among the currently used materials, Beta-Tricalcium Phosphate (B-TCP) may have use in 
sinus floor augmentation procedures.6 B-TCP is a resorbable material that can be replaced by 
bone. For example, a histomorphometrical study7 showed no significant difference in bone 
density volume between test (human sinuses augmented with B-TCP) and control groups 
(augmented with autologous bone). In a similar study, Zerbo and coworkers8 reported that B- 
TCP is an acceptable bone substitute material for sinus augmentation, but the rate of bone 
formation is delayed in comparison to autologous bone. Consequently, the use of bone 
substitutes can become more predictable if they are used in combination with growth factors, 
which have the capacity to accelerate deposition of new bone in association with the graft 
material, thereby shortening the time to achieve adequate consolidation.9 
Platelet rich plasma (PRP), which is a volume of plasma with a concentration of platelets,10 
has been suggested to increase the rate of bone deposition and bone volume in combination 
with bone grafts when used during augmentation procedures.11 It has been demonstrated that 
the application of PRP in dentistry may be beneficial for bone healing.12 The positive impact 
of PRP on bone healing can be attributed to the angiogenetic, proliferative and differentiating 
effect of the transforming growth factor-B (TGF- B) and platelet derived growth factor 
(PDGF) that are present in high concentrations in PRP.13 Therefore, the combination of PRP 
with B-TCP may result in an increased rate of bone formation in a sinus augmentation 
procedure.14
As autologous PRP preparation requires blood to be drawn from the patient, the use of 
allogeneic platelet rich plasma (aPRP) may serve as an alternative option in the case of 
patients who refuse to be subjected to a venipuncture and blood drawing procedure.
The purpose of this report is the presentation of a patient who was treated for sinus 
augmentation by means of aPRP and B-TCP. The report includes the histological evaluation 
of a biopsy harvested from the augmented area.
2. Case Presentation
A 37-year-old non-smoking female was referred to the Department of Periodontology and 
Biomaterials of the Radboud University Nijmegen Medical Centre for periodontal treatment. The 
patient was in good general health, and did not have any subjective dental complaints except bleeding
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during brushing. The dental history revealed that the four third molars were surgically removed in 
childhood, and teeth Nos. 17 and 27 were removed approximately 10 years ago. Also, 
multiple amalgam restorations were present.
During the oral examination and evaluation of the periodontal status, the oral hygiene 
appeared to be inadequate and supragingival calculus was present in the anterila lingual area. 
The bleeding score upon gentle probing was moderate, and probing pocket depths up to 9 mm 
were recorded. Furcation involvement and localized recession were also noticed. The 
radiographic examination showed irregular bone loss up to 70%, especially in the area of the 
maxillary right second molar.
Based on the history, and the clinical and radiographic examinations, the diagnosis was 
generalized chronic periodontitis. The treatment plan included oral hygiene reinforcement, 
supra- and subgingival debridement with hand and ultrasonic instruments and reevaluation of 
the periodontal state at a 3 months interval. Additionally, an extraction of the maxillary right 
first molar during initial periodontal therapy was scheduled due to high mobility (class 3), 
extensive loss of bone support (70% of the root length) and deep probing depths (8-9 mm). 
Surgical intervention for sinus floor elevation and implant replacement of the lost tooth in this 
area was proposed. As the patient did not wish any autologous graft harvesting or blood 
drawing, allogeneic PRP (obtained from a transfusion laboratory) in combination with 
alloplastic graft material (beta-tricalcium phosphate) were selected for the sinus 
augmentation. A re-evaluation of the case after long-term follow-up was also planned. The 
patient was fully informed concerning the treatment to be performed, and signed a written 
consent form.
3. Surgical treatment
Three months after completion of the initial periodontal therapy and extraction of the first 
molar, a reevaluation of the periodontal state was performed indicating no need for 
periodontal surgical therapy. Therefore, the sinus floor augmentation procedure was 
introduced.
Preoperatively, the residual bone height was assessed based on radiographic examination (Fig. 
1a). A 2-stage procedure (first stage, sinus elevation; second stage, placement of implants) 
was performed because the height of the alveolar crest was less than 5 mm.15 The patient 
received antibiotic prophylaxis prior to surgery. The sinus augmentation was then carried out 
according to Tatum.16 After careful elevation of the mucosal layer, the space created between 
maxillary alveolar process and the new sinus floor was filled with 1.5 g B-TCP granules of a 
1000-2000 p,m diameter (Cerasorb, Curasan AC GmbH, Kleinostheim, Germany). The B-TCP 
granules were mixed with the aPRP volume prior to delivery into the opened sinus cavity. 
Care was taken to equally distribute the aPRP over the B-TCP granules. For the preparation of 
the aPRP, a blood volume of 250 cm3 was obtained from a transfusion laboratory 
(Department of Blood Transfusion and Transplantation Immunology, Radboud University 
Nijmegen Medical Center, The Netherlands). The blood sample was compatible (group O-), 
avoiding any immunogenic reactions, and was checked for potentially transmissable diseases. 
The PRP fraction was prepared at a transfusion laboratory (SanQuin Bloedbank, Nijmegen, 
The Netherlands) according to a standard protocol.17 Eleven ml of platelet-rich plasma 
suspension was obtained, and the platelet concentration was 1000 x 106/ml. Normal platelet 
counts range between 150,000/^l and 350,000/^l with an average of about 200,000/^l.
Finally, a bioresorbable collagen membrane of porcine origin (BioGide Perio, Geistlich, 
Wolhusen, Switzerland) was applied to cover the lateral wall defect after the bone graft was
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placed. Complete wound closure was achieved with nonabsorbable, ePTFE sutures (Gore­
Tex, WL Gore Assoc. Inc., Flagstaff, AZ, USA).
Post-surgical pain and edema were controlled with 600 mg ibuprofen, and the patient was 
instructed to rinse twice daily with 0.12% chlorhexidine for two weeks and to use modified 
oral hygiene procedures in the treated area for the first 4 postoperative weeks. The patient was 
examined one week later and the sutures were removed. Radiographic examination was also 
performed (Fig. 1b). The patient was maintained in a supportive care program and received 
full-mouth professional prophylaxis and calculus removal every 4 months 
After a healing period of 6 months, implant placement was performed. A surgical template 
was used and an implant of 13 mm length and 5 mm diameter (Replace Select, Nobel Biocare, 
Gothenburg, Sweden) was inserted in the site of the maxillary right first molar. During this 
procedure, a bone biopsy from the augmented site was harvested using a trephine bur of 5 mm 
diameter. The biopsy was taken in the region of the maxillary right second molar next to the 
site where the implant was placed. Only 4 mm of the apical end of the bone biopsy cylinder 
was taken for histological examination, to guarantee that the augmented region of interest was 
examined. Six months after insertion, the implant was exposed and an abutment was con­
nected. Four weeks later a prosthesis was fabricated (Fig. 1c).
4. Histological and Histomorphometrical evaluation
The biopsy sample was fixed in 4% formaldehyde. Subsequently, it was dehydrated through a 
graded series of ethanol, embedded in methylmethacrylate (MMA), and finally polymerized. 
Longitudinal thin non-decalcified sections (10 .^m) were made with a diamond blade sawing 
microtome. The sections were stained with methylene blue and basic fuchsin and examined 
for histological and histomorphometrical evaluation. The histological evaluation was 
performed with a light microscope (Leica MZ12, Leica BV, Rijswijk, The Netherlands) and 
included a description of the observed tissue response. Additionally, microscopic images were 
projected with a magnification of 25x on a color monitor using a CCD/RGB camera (Sony 
DXC151P, Wetzlar, Germany), and digital image analysis software (Leica Qwin Pro-image 
analysis system, Wetzlar, Germany) was used for the histomorphometrical analysis. The new 
bone area ratio was defined as the area of new bone inside the examined image frame.
The histological examination (Figs. 2a & b) revealed that the sections were composed of 
trabecular bone, marrow spaces with fat cells, and particles of the B-TCP bone substitute. B- 
TCP particles could clearly be observed, but no active degradation appeared to occur as 
characterized by the absence of osteoclast-like cells. The particles showed a wide variety of 
sizes, which may be due to a different degree of resorption or a different level of sectioning 
during the histological processing. The bone had a lamellar structure, and there was a varying 
degree of contact between the B-TCP particles and bone. The lamellae of the bone tissue 
contained osteocytes that were located in lacunae. The bone was clearly distinguishable from 
the B-TCP particles. While new bone lamellae appeared long and thin, the particles of the 
bone substitute material were short with a round shape and were a different shade after 
staining.
Occasionally, fibrous connective tissue was formed around and infiltrated into the TCP 
particles. Sporadically, inflammatory cells surrounded graft particles. Further, large bone 
marrow spaces were present between the formed bone and B-TCP particles, which contained 
fat cells, fibrous tissue, and blood vessels of various diameters. The percentage of new bone, 
the residual bone substitute, marrow space, and fibrous tissue varied among the sections. The 
percentage of bone area had a mean value of approximately 14% (± 4%), whereas the bone 
marrow spaces and graft material particles occupied on average 52% (± 7%) and 33% (±
10%) of the total surface area, respectively.
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(a)
(b)
(c)
Figure 1: Radiographic examination at the following stages: (a) prior to sinus elevation procedure, 
(b) one week after sinus elevation procedure, (c) after implant and suprastructure placement.
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5. One year Re-evaluation
One year after prosthetic rehabilitation, a re-evaluation o f the case was performed. The 
general periodontal status was stable with shallow probing pocket depths and reduced 
bleeding scores. The patient had achieved a very good level o f plaque control. No dental 
complaints were reported. Clinical examination o f the implant placed in the augmented area 
revealed no mobility and healthy peri-implant mucosa. The radiographic examination 
confirmed bone-implant contact without any sign of radiolucency around the implant. During 
the first year of functional loading, additional vertical bone resorption was not observed 
during radiographic examination.
(b)
Figure 2: Histological evaluation of the biopsy: (a) magnification 25x, (b) magnification 100x.
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6. Discussion
Maxillary sinus floor elevation surgery has been developed to increase the height of bone 
available for implant placement in the posterior maxilla. This surgical approach involves the 
elevation o f the sinus membrane and placement o f bone graft material.
As donor site morbidity is often a problem in bone harvesting techniques, there is great 
interest in the use o f bone substitute material. Among various bone substitutes, B-TCP is a 
promising material for augmentation o f the maxillary sinus.6 However, this material has only 
osteoconductive properties, resulting in a delayed rate of bone formation in comparison to 
autologous bone.8 Therefore, an extended postoperative healing period is required before the 
placement o f an implant in a second stage surgery. On the other hand, use o f PRP has been 
suggested to increase the rate of bone deposition and bone volume in combination with bone 
grafts during augmentation procedures.10
Because autologous PRP preparation requires an additional procedure of blood drawing, the 
hypothesis that the use of allogeneic PRP may serve as an alternative option was evaluated in 
this case. Considering the limitations of the present report (a single case), the addition of 
aPRP did not apparently result in a remarkable increase in bone formation. In a 
histomorphometrical human study, Zerbo et al.8 reported that the average new bone volume 
formed in the augmented sinus with the use of B-TCP particles did not exceed 20% at a 6- 
months postoperative period.
In another human study, Wiltfang and coworkers14 evaluated the effect o f autologous PRP in 
combination with B-TCP particles in sinus augmentation procedures, and they demonstrated 
that the formation of new bone was about 10% higher when autologous PRP was used. The 
volume of new bone reached a mean value of 29% in the non-PRP group (only B-TCP 
particles), and 38% in the PRP group (combination o f PRP and B-TCP particles). While that 
study and this case cannot be directly compared, less bone formation was observed in the 
present case with the use o f allogeneic PRP. Bone formation did not exceed a mean 
percentage o f 14% of the total examined area. An explanation for the lack o f beneficial effect 
might be that in this report allogeneic PRP was used. The allogeneic PRP may not have the 
same properties as the autologous material.18 Furthermore, in the current study PRP was 
applied without the use o f thrombin. The platelet concentrate is activated by the addition of 
thrombin and calcium chloride resulting in the release of a cascade of growth factors from the 
alpha granules12. Some authors have questioned the necessity o f using thrombin.13,19 
Dugrillon et al.19 proposed that PRP gel formation can be performed only with the addition of 
calcium and no other activator is required. The mixture of PRP with the bone graft material 
may present a sufficient viscosity and induced coagulation and growth factors release. Also, 
Wiltfang and coworkers14 reported more bone formation in sinus elevation cases applying 
PRP compared to control group (no application of PRP) despite that no thrombin was used.
In addition, it must be emphasized that conflicting results have been reported in the literature 
regarding the beneficial effect of the autologous PRP on bone formation in augmentation 
procedures. Raghoebar et al.20 did not observe any additional benefit on bone formation when 
they applied PRP in combination with autologous bone grafts in sinus floor elevation. 
Preparation time and centrifugation forces may play a role on the PRP effectiveness. The 
active secretion of these growth factors is initiated by the clotting process of blood and begins 
within 10 minutes after clotting18. More than 95% of the pre-synthesized growth factors are 
secreted within one hour so that, PRP must be developed in an anticoagulated state and should 
be used within 10 minutes after clot initiation21. However, the concentrated platelets can 
remain viable for up to 8 hours in the anticoagulated state21. Moreover, the centrifugation 
forces may be a critical step in PRP preparation and the mechanical forces may activate
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platelets, with the consequence of loosing the granular load that contains the growth factors 
into the concentrated plasma volume19.
Furthermore, this histological study confirmed that B-TCP is an acceptable bone substitute 
material for sinus augmentation, but the rate o f bone formation was delayed at 6 months. The 
synthetic material occupied one-third of the histological section, and some particles did not 
reveal any sign o f degradation. This has been reported by other authors.8 
In summary, the present case report shows that the use of aPRP in a sinus augmentation 
procedure neither provoked any adverse tissue reaction nor caused any discomfort to the 
patient. On the other hand, the beneficial contribution o f allogeneic PRP to bone formation 
after mixture with a synthetic bone substitute in sinus augmentation procedures is not defined. 
Within the limitations of this report, allogeneic PRP did not appear to have any additional 
effect on bone formation in combination with alloplastic graft material in sinus elevation 
surgery. However, the treatment outcome was successful resulting in adequate bone volume 
that could host the oral implant for proper tooth replacement and sufficient masticatory 
function.
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Chapter 7
SUM MARY, ADDRESS TO THE AIMS, 
CLOSING REMARKS AND FUTURE PERSPECTIVES
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1. Summary and address to the aims 
Introduction
Current research focuses on parameters that may improve the bone response to oral implants. 
One of the investigated parameters is the effect of growth factors on bone healing around 
medical and oral implants. Platelet rich plasma (PRP) is a new approach in tissue regeneration 
and a developing area for clinicians and researchers. It is used in various surgical fields, 
including oral and maxillofacial surgery. PRP is prepared out o f the patient’s own blood and 
contains growth factors that influence wound healing. Among them, platelet-derived growth 
factor (PDGF), transforming growth factor (TGF), insulin-like growth factor (IGF) and epi­
dermal growth factor (EGF) play a pivotal role in tissue repair mechanisms. Although the 
growth factors and mechanisms involved are still poorly understood, the easy application of 
PRP in the clinic and its possible beneficial outcome, including reduction of bleeding, rapid 
soft tissue healing and bone regeneration, holds promise for new treatment approaches. 
However, animal studies and human trials demonstrate conflicting results regarding the 
application o f PRP. Well-designed studies are needed to provide solid evidence o f the 
capacity PRP. Therefore, the aim of the current thesis was to elucidate the effect o f Platelet 
Rich Plasma on bone formation and to investigate whether the growth factors included in 
Platelet Rich Plasma can improve the bone response to oral implants, especially during the 
early post-implantation healing phase.
The effect o f Platelet-Rich Plasma (PRP) on bone regeneration in dentistry: a systematic 
review
Objective of chapter 2 was to review systematically the reported effects of platelet-rich 
plasma (PRP) on bone regeneration. Up to June 2006, MEDLINE and Cochrane databases 
were explored with different combinations o f three search terms: “PRP”, “bone regeneration”, 
“dentistry” and their synonyms. Inclusion criteria were human controlled clinical trials 
designed to treat maxillofacial bony defects with application of PRP (test) or without PRP 
(control), including at least 5 patients with a follow-up period of more than 3 months and 
using clinical assessment, radiography, histology and histomorphometry as evaluation. 
Literature search, selection of eligible articles, and data extraction were carried out 
independently by two readers. The literature search revealed 108 references, o f which 17 were 
selected for further analysis. Finally, 9 articles fulfilling the inclusion criteria were selected to 
review systematically. Due to the substantial heterogeneity o f the studies it was not possible 
to statistically analyze the data. An attempt was made to compare results from studies that 
used similar outcome measures by calculating and adding Confidence Intervals to the data 
presented in the original papers. Differences in treatment effects for periodontal defects in 
terms o f clinical attachment level (CAL) were significant (ranging from 0.8 to 3.2 mm). The 
reported effects o f PRP in sinus elevation (compared to their controls) were less than 10%. It 
was concluded that evidence for beneficial effects of PRP in treatment of periodontal defects 
may exist. The beneficial effects o f PRP in sinus elevation appeared to be weak. No  
conclusions can be drawn about other applications o f PRP in dentistry.
The effect o f Platelet-Rich Plasma (PRP) on the bone healing around Ca-P coated and 
non-coated oral implants in trabecular bone
The effect of local application of autologous Platelet-Rich Plasma (PRP) on bone healing in 
combination with the use of titanium (Ti) implants with two different surface configurations 
was investigated in the third chapter. PRP fractions were obtained from venous blood sample 
of six goats and applied via gel preparation and subsequent installation in the implant site, or 
via dipping o f the implant in PRP liquid before insertion. A total o f 36 implants (18 non­
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coated and 18 CaP-coated) were placed into the goat femoral condyles (trabecular bone). The 
animals were sacrificed at 6 weeks after implantation and implants with surrounding tissue 
were processed for light microscopical evaluation. Besides subjective description of the 
histological findings, histomorphometrical variables were also evaluated (the bone-implant 
contact and the bone mass adjacent to the implant). Significantly increased interfacial bone- 
to-implant contact was observed for all the three groups of CaP-coated implants and the 
Ti/liquid group (non-coated implant with PRP liquid) compared to the other two non-coated 
Ti groups (with PRP gel or without PRP). The evaluation of the bone mass close to implant 
surface indicated that all the groups induced a significant increase of the bone mass except 
both PRP gel groups. Consequently, the results showed that magnetron sputtered Ca-P 
coatings can improve the integration of oral implants in trabecular bone. The additional use of 
PRP did not offer any significant effect on the bone response to the Ca-P coated implants, 
while PRP in a liquid form showed a significant effect on bone apposition to roughened 
titanium implants during the early post-implantation healing phase.
The effect o f Platelet-Rich Plasma (PRP) on the early bone formation around Ca-P coated 
and non-coated oral implants in cortical bone
The purpose of chapter 4 was to analyze the effect of local application of PRP on the early 
healing of cortical bone around Ti implants with two different surface configurations. Six 
goats were used in this study. PRP fractions were obtained from venous blood sample of the 
goats and administered immediately before implant insertion. PRP was applied via gel 
preparation and installation of the gel into the implant site, or via dipping of the implants in 
PRP fraction before insertion. A total of 36 implants (18 non-coated and 18 CaP-coated) were 
placed into the tibial cortical bone. The animals were sacrificed at 6 weeks after implantation 
and implants with surrounding tissue were prepared for histological examination. 
Histomorphometrical variables like the percentage of implant surface with direct bone- 
implant contact and the percentage of new and old bone adjacent to the implant were 
evaluated. More interfacial bone-to-implant contact was observed for all the three groups of 
CaP-coated implants and the Ti/PRP liquid group. All groups revealed similar percentages of 
old and new bone adjacent to the implant. It was concluded that the additional use of PRP did 
not offer any effect on the early cortical bone response to the Ca-P coated implants, while 
PRP in a liquid form showed a tendency to increase bone apposition to roughened titanium 
implants.
The effect o f a low dose o f transforming growth factor P1 (TGF-^1) on the early bone- 
healing around oral implants inserted in trabecular bone
Transforming growth factor P1 (TGF-P1) has been shown to stimulate bone healing in several 
animal models and may influence bone response directly after implant installation. Aim of 
chapter 5 was to investigate the effect of a low dose of TGF-P 1, on the early bone healing 
around oral implants placed in trabecular bone. Twenty-four cylindrical screw type implants 
were used and TGF-P1 in two different concentrations was applied on sixteen of them. Each 
animal received three implants: one Ti (control), one Ti-TGF05 (Ti loaded with 0.5 |ig TGF- 
P1), and one Ti-TGF10 (Ti loaded with 1.0 |ig TGF-P 1). The eight animals were sacrificed at 
6 weeks after implantation and implants with surrounding tissue were retrieved for 
histological preparation and histomorphometrical evaluation. Light microscopical analysis 
showed the occurrence of an intervening fibrous tissue layer around about half of the TGF-P1 
loaded implants. Further, the histomorphometrical measurements revealed that the Ti implants 
demonstrated the highest percentage of bone-implant contact (65 ± 4%), while Ti-TGF10 
implants showed the lowest amount (45 ± 12%). The difference between these two groups 
was statistically significant. On basis of the results, it is concluded that TGF-P1 may have a
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negative influence on the integration of oral implants in trabecular bone during the early post­
implantation healing phase.
Sinus floor elevation using Platelet Rich Plasma (PRP) and beta-Tricalcium Phosphate (fi- 
TCP): case report and histological evaluation
In chapter six, a case report revealed that the use of allogeneic PRP in a sinus augmentation 
procedure neither provoked any adverse tissue reaction nor caused any discomfort to the 
patient. On the other hand, the beneficial contribution of PRP to bone formation after mixture 
with a synthetic bone substitute in sinus augmentation procedures was questioned. Within the 
limitations of this study, PRP did not appear to have any additional effect on bone formation 
in combination with alloplastic graft material in sinus elevation surgery. However, the 
treatment outcome was successful resulting in adequate bone volume that could host the oral 
implant for proper tooth replacement and sufficient masticatory function.
2. Closing remarks and future perspectives
In the present thesis, the effect of Platelet Rich Plasma (PRP) on the bone response to oral 
implants was studied. It was hypothesized that growth factors as available in PRP can 
improve bone apposition on the implant surface. PRP failed to enhance significantly bone 
regeneration around oral implants, especially during the early post-implantation healing 
phase. Also, TGF-P1 (a growth factor present in PRP with osteogenic capacity) did not 
promote bone formation combined with implant placement. All observations were supported 
by histological and histomorphometrical parameters. Histomorphometry was selected as it 
appears a reliable and widely used quantitive method for assessing the bone-implant interface 
(Meredith 1998).
The current results endorsed the disagreement for the efficacy of PRP. This topic certainly 
generates much passion and debate amongst specialists in the field of oral reconstruction. The 
clinical effect of PRP is based on the local delivery of a wide range of growth factors and 
proteins that may enhance wound healing by mimicking the physiological tissue process in an 
exaggerated motive. While nobody can dispute the benefits of growth factors in wound 
healing, little is known regarding the role and the optimal concentration of each growth factor 
independently in bone regeneration. Several reviews, including those presented in the current 
thesis, support a minimal to weak evidence for the beneficial effect of PRP on bone 
regeneration (Schilephake 2002, Boyapati & Wang 2006, Plachokova et al. 2008, Nikolidakis 
& Jansen 2008). Furthermore, the systematic reviews revealed a serious lack of good quality 
trials, which hamper any attempt to draw solid conclusions on the relevance of PRP 
application. Although the reported effects of PRP on bone healing in humans are 
contradictory, PRP has been proposed in the dental practice for treatment of periodontal 
defects, sinus lift procedures, oral-maxillofacial reconstructions, alveolar ridge augmentations 
and bone formation in extraction sockets (Marx 2004, Plachokova et al. 2008).
Regarding the use of PRP in implant dentistry, the current thesis could not observe any 
benefit of PRP on bone formation around oral implants either in trabecular or cortical bone 
type. As jaw bone consists of a cortical layer and a trabecular interior of which the relative 
proportion depends on the jaw region, it was considered to be relevant to evaluate PRP 
biological behaviour in both bone types. Additionally, the efficacy of PRP was tested for 
rough calcium phosphate (CaP) coated and non-coated implants as both implant types are 
available in the market. Lack of benefit was also observed after incorporation of PRP into 
alloplastic material in the sinus case. However, PRP in a liquid form (without coagulation 
activator) revealed a tendency for an additional effect on bone apposition to roughened
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titanium implants. On the other hand, the implants provided with a RF magnetron sputtered 
CaP coating demonstrated superior behavior regarding bone apposition and bone implant 
contact and additional clinical trials are necessary to confirm this superiority in terms of 
implant survival and success after long term evaluation.
Our results confirm that the clinical relevance of PRP application in bone regeneration is 
difficult to elucidate. In vitro data suggest that PRP is a promising treatment option. However, 
in vitro studies extremely simplify the real clinical situation where multiple growth factors 
and multiple cell types interact in a complicated manner making any extrapolation of the in 
vitro data quite cumbersome (Freymiller & Aghaloo 2004). Further, the analysis of the animal 
and human studies outlines the controversial nature of this issue and creates confusion 
regarding the beneficial effect of PRP in oral surgery. Therefore, well-designed studies are 
needed to provide solid evidence of the PRP capacity on bone regeneration. First of all, a 
consensus is necessary for several unclear issues regarding PRP preparation and application, 
like use of proper cell separator devices, pattern of centrifugation steps, adequate number of 
platelets (baseline and treatment dose), testing for growth factors efficiency, ideal 
concentration of growth factors and necessity for coagulation activators. The currently 
obtained conflicting the results can be easily explained by the chaotic divergence for all these 
parameters among the studies. Future studies should assess and clarify all the above issues 
before animal and human studies attempt to support the potential beneficial effect of PRP 
treatment in bone regeneration.
Furthermore, many reports support the use of PRP by proposing several advantages such as 
the autogenous nature of the biomaterial and the quite easy and fast preparation method. 
However, it is also important to consider the cost versus outcome benefit of PRP. The current 
status of PRP efficacy may not justify the cost to the practitioner of obtaining the 
armamentarium or perhaps even more importantly, the cost to the patient for paying this 
treatment option. Additionally, from a clinician’s point of view it is important to point to the 
practical aspects related to PRP preparation, which involves an additional step in the surgical 
procedure requesting extra time and effort. Furthermore, PRP preparation requires blood to be 
drawn from the patient who has to be subjected to a venipuncture and blood drawing 
procedure contributing to additional inconvenience for the treatment. Evidently, there is a lack 
of clinical studies evaluating the cost benefit ratio, patient discomfort, and patient satisfaction 
regarding PRP application.
Also in the current thesis, TGF-P1 was evaluated as it is a growth factor present in PRP and is 
supposed to possess osteogenic capacity. However, the applied single dose of TGF-P1 could 
not promote bone healing close to implant surface and it was suggested that the enhancement 
of bone regeneration may be dependent on a delayed release pattern. Further animal studies 
are needed to assess the potential benefit of this growth factor.
Under the experimental conditions, as described in the current thesis, the additional use of 
PRP and TGF-P in implant dentistry cannot be recommended in a daily practice approach.
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Chapter 8
SAM ENVATTING, AFSLUITENDE OPM ERKINGEN EN TOEKOMSTVISIE
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Huidig onderzoek richt zich op parameters, welke de botreactie na plaatsing van 
tandheelkundige implantaten verbeteren. Één van deze parameters is het effect van 
groeifactoren op de botgenezing rond medische en tandheelkundige implantaten. Platelet-rich 
plasma (PRP) is een nieuwe benadering in het veld van weefselregeneratie en een zich 
ontwikkelend gebied voor clinici en onderzoekers. PRP wordt gebruikt in verschillende 
chirurgische disciplines, waaronder mond-, kaak- en aangezichtchirurgie. PRP wordt bereid 
uit het bloed van de patiënt zelf en bevat groeifactoren die de wondgenezing beïnvloeden. 
Vooral de groeifactoren platelet-derived growth factor (PDGF), transforming growth factor 
(TGF), insulin-like growth factor (IGF) en epidermal growth factor (EGF) zijn interessant 
vanwege hun belangrijke rol in weefselherstel. Hoewel over het gebruik van groeifactoren en 
gerelateerde mechanismen nog veel onduidelijk is, lijkt PRP veelbelovend, temeer omdat PRP 
gemakkelijk bereid en klinisch toegepast kan worden. Echter, dierexperimenteel onderzoek en 
human trials laten tot dusver geen eensluidende resultaten zien v.w.b. de beoogde gunstige 
effecten van PRP. Derhalve was de doelstelling van het in deze thesis beschreven onderzoek 
het ophelderen van het effect van Platelet-Rich Plasma op botvorming en het bestuderen van 
mogelijke positieve effecten van groeifactoren in Platelet-Rich Plasma op de botreactie 
rondom een geplaatst tandheelkundig implantaat, vooral tijdens de initiële fase na implantatie.
Het effect van Platelet-Rich Plasma (PRP) op botregeneratie in de tandheelkunde: een 
systematische review
Het doel van hoofdstuk 2 was het systematisch herzien van gepubliceerde effecten van 
platelet-rich plasma (PRP) op botregeneratie. Databases van MEDLINE en Cochrane werden 
(tot juni 2006) geraadpleegd met verschillende combinaties van de drie zoektermen: “PRP”, 
“bone regeneration” en “dentistry” (en synoniemen hiervan). De ‘hits’ uit de 
literatuurraadpleging dienden te voldoen aan de volgende criteria: humane klinische studies 
gericht op de behandeling van maxillofaciale botdefecten, waarbij gebruik gemaakt wordt van 
PRP (test) o f niet (controle), met minimaal 5 patiënten en een follow-up van minimaal 3 
maanden, gebruikmakend van de volgende evaluatietechnieken: klinische beoordeling, 
radiografie, histologie en/of histomorfometrie. De literatuurraadpleging, selectie van 
geschikte wetenschappelijke artikelen en data extractie werd onafhankelijk uitgevoerd door 2 
personen. De literatuurraadpleging leverde 108 ‘hits’ op, waarvan er initieel 17 werden 
geselecteerd. Na controle op vereiste criteria, werden uiteindelijk 9 wetenschappelijke 
artikelen geselecteerd voor een systematische review. Gezien de grote verschillen in opzet van 
de studies was het onmogelijk de data statistisch te analyseren. Derhalve werd getracht de 
resultaten te vergelijken van studies, waarin dezelfde parameters gebruikt werden middels het 
berekenen en toevoegen van betrouwbaarheidsintervallen aan de hand van de originele data 
van de studies. Significante verschillen werden gevonden voor behandelingseffecten voor 
parodontale defecten, meer specifiek voor clinical attachment level (CAL; range 0.8 -  3.2 
mm). De beschreven effecten van PRP voor sinus elevatie (vergeleken met de controles) 
waren minder dan 10%. De conclusie van de systematische review was dat bewijs was 
geleverd voor positieve effecten van PRP voor de behandeling van parodontale defecten.
Voor positieve effecten van PRP voor sinus elevatie was het bewijs slechts zwak. Verdere 
conclusies over het gebruik van PRP voor andere toepassingen in de tandheelkunde konden 
niet worden getrokken.
Het effect van Platelet-Rich Plasma (PRP) op botgenezing rond CaP-gecoate en niet- 
gecoate tandheelkundige implantaten in trabeculair bot
Het effect van plaatselijk gebruik van autoloog Platelet-Rich Plasma (PRP) op botgenezing in
1. Samenvatting en evaluatie van de doelstellingen
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combinatie met titanium (Ti) implantaten met twee verschillende oppervlakte configuraties 
was het onderwerp in hoofdstuk 3. PRP werd gewonnen uit veneus bloed van zes geiten en 
aangebracht op de plek van implantatie in de vorm van een gel o f via het dompelen van het 
implantaat in de PRP-vloeistof vóór plaatsing van het implantaat. Een totaal aantal van 36 
implantaten (18 niet-gecoat; 18 CaP-gecoat) werd geplaatst in femorale condylen van geiten 
(trabeculair bot). De dieren werden 6 weken na implantatie geofferd, waarna de implantaten 
met omliggend weefsel werden verwerkt voor histologische evaluatie. Naast een subjectieve 
beschrijving van de histologische bevindingen, werden histomorfometrische variabelen 
geëvalueerd (bot-implantaat contact en botmassa direct rond het implantaat). Significant 
hoger bot-implantaat contact werd aangetoond voor alle drie de groepen met CaP-gecoate 
implantaten en de groep met ongecoate implantaten ondergedompeld in PRP-vloeistof t.o.v. 
de twee andere groepen met ongecoate implantaten (met PRP-gel o f zonder PRP). Evaluatie 
van de botmassa rond het implantaat toonde dat voor alle groepen een significante toename 
met uitzondering van beide groepen met PRP-gel. Geconcludeerd werd dat CaP-coatings de 
integratie van tandheelkundige implantaten in trabeculair bot kunnen verbeteren. Additioneel 
gebruik van PRP had geen significant effect op de botreactie rond CaP-gecoate implantaten, 
terwijl PRP-vloeistof wel leidt tot een significante verbetering van het botcontact met titanium 
implantaten in de initiële genezingsfase na implantatie.
Het effect van Platelet-Rich Plasma (PRP) op de initiële botvorming rond CaP-gecoate en 
niet-gecoate tandheelkundige implantaten in corticaal bot
Het doel van hoofdstuk 4 was het analyseren van het effect van plaatselijke toedienen van 
PRP op de initiële botgenezing van corticaal bot rond titanium implantaten met twee 
verschillende oppervlakte configuraties. Zes geiten werden gebruikt in deze studie. PRP werd 
gewonnen uit veneus bloed van de geiten en toegediend direct voorafgaand aan het plaatsen 
van de implantaten. PRP werd gebruikt in de vorm van een gel op de plaats van implantatie of 
via het onderdompelen van de implantaten in een PRP-vloeistof vóór implantatie. In corticaal 
bot van de tibia werden in totaal 36 implantaten (18 niet-gecoat; 18 CaP-gecoat) geplaatst. De 
dieren werden geofferd op 6 weken na implantatie, waarna implantaten met omliggend 
weefsel werden verwerkt voor histologische evaluatie. Verder werden histomorfometrische 
variabelen, zoals bot-implantaat contact en het percentage nieuw en oud bot rond het 
implantaat, geanalyseerd. Een hoger bot-implantaat contact werd waargenomen voor alle drie 
de groepen met CaP-gecoate implantaten en de niet-gecoate implantaten met PRP-vloeistof. 
Verder waren de percentages oud en nieuw bot voor alle groepen gelijk. De conclusie van 
deze studie was dat additioneel gebruik van PRP geen effect heeft op de initiële botreactie 
rond CaP-gecoate implantaten, terwijl een neiging werd waargenomen naar verhoogde 
botafzetting rond niet-gecoate implantaten wanneer PRP-vloeistof werd gebruikt.
Het effect van een lage dosis transforming growth factor @1 (TGF-ftl) op de initiële 
botgenezing rond tandheelkundige implantaten in trabeculair bot
Van transforming growth factor P1 (TGF-P1) is bekend dat het botgenezing stimuleert in 
verscheidene proefdiermodellen en mogelijk de botreactie beïnvloedt direct na plaatsing van 
een implantaat. Het doel in hoofdstuk 5 was te onderzoeken o f een lage dosis TGF-P1 een 
effect heeft op de initiële botgenezing rond tandheelkundige implantaten in trabeculair bot. 
Hiertoe werden 24 cilindrische, schroefvormige implantaten gebruikt, waarop al dan niet een 
dosis TGF-P1 werd aangebracht. In elk van de 8 dieren werden 3 implantaten geplaatst: één 
titanium (controle), één Ti-TGF05 (Ti met 0.5 |ig TGF-P1) en één Ti-TGF10 (Ti met 1.0 |ig 
TGF-P1). De dieren werden 6 weken na implantatie geofferd, waarna de implantaten met 
omliggend weefsel werden verwerkt voor histologie en -morfometrie. Lichtmicroscopische 
analyse toonde dat ongeveer de helft van de implantaten met een dosis TGF-P1 werden
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omgeven door een laag fibreus weefsel. Histomorfometrie toonde verder dat botcontact 
significant hoger was voor titanium implantaten (65 ± 4%) t.o.v. Ti-TGF10 (45 ± 12%). Op 
basis van de resultaten van deze studie werd geconcludeerd dat TGF-ß1 wellicht een negatief 
effect heeft op de integratie van tandheelkundige implantaten in trabeculair bot tijdens de 
initiële fase na plaatsing.
Sinus bodem elevatie met Platelet-Rich Plasma (PRP) en beta-tricalciumfosfaat (ß-TCP): 
case report en histologische evaluatie
Hoofdstuk 6 laat middels een case report zien dat het toedienen van allogeen PRP in een sinus 
bodem elevatie procedure zowel geen nadelige weefselreactie als ongemak voor de patiënt 
teweegbrengt. Daar staat tegenover men zich nog steeds kan afvragen o f er gunstige effecten 
van PRP zijn op botvorming in sinus bodem elevatie procedures, na het mixen met een 
synthetische botvervanger. Binnen de beperkingen van deze studie werden namelijk geen 
effecten van PRP op botvorming waargenomen, wanneer aangebracht in combinatie met 
alloplastisch materiaal in een sinus bodem elevatie procedure. Echter, het dient vermeld te 
worden dat het resultaat van de behandeling succesvol was en voldoende botvolume 
genereerde voor tandvervanging en kauwfunctie.
2. Afsluitende opmerkingen en toekomstvisie
In de onderhavige thesis werd het effect van Platelet-Rich Plasma (PRP) op de botreactie rond 
tandheelkundige implantaten onderzocht. De veronderstelling was dat groeifactoren, zoals 
aanwezig in PRP, de botaanhechting aan het implantaat-oppervlak kunnen verbeteren. 
Toediening van PRP leidde echter niet tot significant verhoogde botregeneratie rond 
tandheelkundige implantaten in de initiele fase na plaatsing. Bovendien stimuleerde ook TGF- 
ß1 (een groeifactor met osteogene capaciteit in PRP) niet de botvorming na het plaatsen van 
een implantaat. Alle bevindingen werden bevestigd door histologische en -morfometrische 
parameters. Histomorfometrie werd gebruikt omdat het een betrouwbare en veelvuldig 
gebruikte methode is om kwantitatieve informatie te krijgen omtrent het bot-implant 
grensvlak (Meredith 1998).
De huidige resultaten bevestigen tegenstrijdige publicaties over de werkzaamheid van PRP. 
Dit onderwerp genereert ongetwijfeld veel stof tot discussie onder specialisten in het veld van 
orale reconstructie. Het klinisch effect van PRP is gebaseerd op de lokale afgifte van een 
range van groeifactoren en eiwitten, die de wondgenezing zouden kunnen verbeteren door het 
overdreven (i.e. met overdosis groeifactoren) nabootsen van een fysiologisch proces. Hoewel 
niemand de voordelen van groeifactoren in wondgenezingsprocessen kan betwisten, is er 
maar weinig bekend over de rol en optimale concentratie van iedere specifieke groeifactor in 
botregeneratie. Verschillende reviews, waaronder de in deze thesis opgenomen reviews, 
leveren minimaal tot zwak bewijs voor gunstige effecten van PRP op botregeneratie 
(Schliephake 2002; Boyapati & Wang 2006; Plachokova et al. 2008; Nikolidakis & Jansen 
2008). Verder toonden systematische reviews dat er een gebrek is aan kwalitatief goede trials, 
waardoor het trekken van eensluidende conclusies omtrent de relevantie van PRP toediening 
bemoeilijkt wordt. Ondanks het feit dat de resultaten van PRP op botgenezing tegenstrijdig 
zijn, wordt PRP aanbevolen voor gebruik in de tandheelkundige praktijk voor de behandeling 
van parodontale defecten, sinus bodem elevatie procedures, alveolair bot vermeerdering 
(Marx 2004; Plachokova et al. 2008).
Voor toepassing van PRP bij het plaatsen van tandheelkundige implantaten kon het onderzoek 
beschreven in de onderhavige thesis geen voordeel aantonen v.w.b. botvorming rond 
tandheelkundige implantaten in trabeculair en corticaal bot. Aangezien kaakbot bestaat uit een 
corticale laag gevuld met trabeculair bot, waarbij de verhoudingen varieren met kaakregio,
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werd verondersteld dat het relevant was om de biologische reactie op PRP te onderzoeken in 
beide typen botweefsel. Bovendien werd de werkzaamheid van PRP getest in combinatie met 
zowel CaP-gecoate als niet-gecoate implantaten, welke beide beschikbaar zijn op de 
implantatenmarkt. Ook de toepassing van PRP in combinatie met alloplastisch materiaal in 
een sinus bodem elevatie procedure bleek geen gunstige effecten te hebben. Echter, in 
vloeibare vorm (zonder coagulatie-activator) bleek er een tendens te bestaan voor een gunstig 
effect van PRP op botaanhechting tegen ruwe titanium implantaten. Daar staat tegenover dat 
implantaten met een CaP-coating superieur zijn in het licht van botaanhechting en bot- 
implantaat contact. Vervolgonderzoek in de vorm van clinical trials is noodzakelijk om deze 
superioriteit te bevestigen na langere implantatie-periodes.
De resultaten beschreven in dit proefschrift bevestigen dat het moeilijk is de klinische 
relevantie van PRP-toepassing voor botregeneratie op te helderen. In vitro data suggereren dat 
PRP een veelbelovende behandelingsoptie vertegenwoordigt. Echter, in vitro studies zijn een 
simplificatie van de werkelijke klinische situatie, waarin meerdere groeifactoren en celtypen 
complexe interacties ondergaan, en derhalve lastig te extrapoleren (Freymiller & Aghaloo 
2004). De analyse van dierexperimentele en humane studies schetst verder een beeld van de 
controversie op dit gebied en creeert onduidelijkheid omtrent gunstige effecten van PRP in de 
mond-, kaak- en aangezichtchirurgie. Daarom is het noodzakelijk gedegen-opgezette studies 
uit te voeren om eensluidend bewijs te verkrijgen over de capaciteit van PRP in 
botregeneratie. Primair dient consensus te worden verkregen over verschillende onduidelijke 
stappen in het proces van PRP-bereiding en toediening, zoals celscheiding, centrifugatie- 
stappen, platelet-concentraties (bloed- en behandelingsconcentratie), tests voor groeifactor 
werkzaamheid, optimale concentraties van individuele groeifactoren en noodzaak voor 
coagulatie-activators. De verkregen tegenstrijdige resultaten kunnen eenvoudig worden 
verklaard uit de verschillen in de hierboven beschreven stappen in de bereiding en toediening 
van PRP. Toekomstige studies dienen zich te richten op de opheldering van deze zaken 
alvorens dierexperimenten en human trials kunnen worden opgezet naar het effect van PRP op 
botregeneratie.
Veel publicaties ondersteunen het gebruik van PRP door te stellen dat PRP voordelen biedt, 
zoals autogeniciteit van het materiaal en de snelle en makkelijke bereidingsmethode. Echter, 
het is van belang om de kosten af te zetten tegen het resultaat. De huidige status van PRP 
werkzaamheid rechtvaardigt waarschijnlijk niet de kosten voor de uitvoerder voor het 
verkrijgen van het instrumentarium voor PRP-bereiding, o f zelfs nog belangrijker de kosten 
voor de patiënt om te betalen voor de behandeling. Daarnaast is het voor een clinicus 
belangrijk te wijzen op de praktische aspecten van PRP-bereiding, hetgeen inhoudt dat er een 
extra ingreep gedaan moet worden met bijbehorende tijdsconsumptie en moeite. Deze ingreep 
gaat gepaard met het verkrijgen van bloed middels een venipuncture, welke zorgt voor 
additioneel onbehagen. Er is dus duidelijk een tekort aan klinische studies met focus op de 
ratio kosten/baten, onbehagen voor de patiënt en patiënt-tevredenheid over PRP-toediening. 
Naast PRP werd in deze thesis TGF-ß1 onderzocht, een groeifactor aanwezig in PRP met 
veronderstelde osteogene capaciteit. Een individuele dosis TGF-ß1 bleek niet in staat 
botgenezing te bevorderen. Dit zou kunnen liggen aan de mogelijkheid dat botregeneratie 
afhankelijk is van een vertraagd release patroon. Dierexperimentele studies omtrent dit 
onderwerp zijn noodzakelijk om dit te kunnen onderzoeken.
De onderzoeken beschreven in deze thesis en uitgevoerd onder experimentele condities geven 
geen aanleiding om het gebruik van PRP en TGF-ß aan te bevelen in de dagelijkse praktijk.
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